var title_f11_60_12224="Atrial and ventricular septal defects PI";
var content_f11_60_12224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrial and ventricular septal defects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 337px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a drawing of a normal heart. The heart has 4 chambers: right atrium, left atrium, right ventricle, and left ventricle. A child with an atrial septal defect has a hole between the right atrium and the left atrium. A child with an ventricular septal defect has a hole between the right ventricle and the left ventricle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12224=[""].join("\n");
var outline_f11_60_12224=null;
var title_f11_60_12225="Melanoma - Impact of T stage on prognosis";
var content_f11_60_12225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Melanoma - Impact of T stage on prognosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 639px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Twenty-year survival rates comparing the different T categories (top) and the stage groupings (bottom) for stages I and II melanoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12225=[""].join("\n");
var outline_f11_60_12225=null;
var title_f11_60_12226="DBE NSAID induced stricture";
var content_f11_60_12226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    DBE NSAID induced stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Proximal ileal nonsteroidal antiinflammatory drug (NSAID)-induced diaphragm-like stricture diagnosed by double balloon enteroscopy (DBE).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Louis-Michel Wong Kee Song, MD, FRCP(C).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12226=[""].join("\n");
var outline_f11_60_12226=null;
var title_f11_60_12227="Muscarinic receptors in asthma";
var content_f11_60_12227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Pharmacology of bronchodilators",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Localization of muscarinic receptor subtypes. M1 receptors mediate increased cholinergic transmission; M2 autoreceptors act as a negative feedback loop in neuronal transmission and promote acetylcholine re-uptake, limiting bronchoconstriction; M3 receptors result in contraction of airway smooth muscle.",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; ACh: acetylcholine; EpDRF: epithelium-derived relaxant factor; NO: nitric oxide.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Calverley PM. Pharmacology of Bronchodilators Used in Obstructive Airway Disease. In: The Role of Anticholinergics in Chronic Obstructive Pulmonary Disease and Chronic Asthma, Barnes PJ, Buist AS, (Eds), Gardiner-Caldwell Communications Limited, Cheshire, UK 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12227=[""].join("\n");
var outline_f11_60_12227=null;
var title_f11_60_12228="ETT overinflation CT";
var content_f11_60_12228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomographic scans of the chest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 524px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper image shows an endotracheal tube (ETT) at the level of the mid-trachea; the wide ring of air surrounding teh tube suggests ETT cuff over-inflation, a risk factor for iatrogenic tracheal injury. The lower image demonstrates a focal injury to the posterior tracheal wall and herniation of the cuff into the posterior mediastinum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12228=[""].join("\n");
var outline_f11_60_12228=null;
var title_f11_60_12229="Trucut apparatus seen by EUS";
var content_f11_60_12229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Distinct echo features of trucut apparatus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic image showing distinct patterns of the components of the trucut apparatus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Levy, MD and Mauritis J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12229=[""].join("\n");
var outline_f11_60_12229=null;
var title_f11_60_12230="Leucovorin rescue dose";
var content_f11_60_12230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DRUG%2F64513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DRUG%2F64513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Leucovorin rescue dose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12230=[""].join("\n");
var outline_f11_60_12230=null;
var title_f11_60_12231="Gemifloxacin: Drug information";
var content_f11_60_12231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gemifloxacin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/19/22837?source=see_link\">",
"    see \"Gemifloxacin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6758349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Factive&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4799816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Factive&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F175837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Quinolone;",
"     </li>",
"     <li>",
"      Respiratory Fluoroquinolone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F175819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"     Oral: 320 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute exacerbations of chronic bronchitis:",
"     </b>",
"     Oral: 320 mg once daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Community-acquired pneumonia (mild-to-moderate):",
"     </b>",
"     Oral: 320 mg once daily for 5 or 7 days (decision to use 5- or 7-day regimen should be guided by initial sputum culture; 7 days are recommended for MDRSP,",
"     <i>",
"      Klebsiella",
"     </i>",
"     , or",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     infection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sinusitis (unlabeled use):",
"     </b>",
"     Oral: 320 mg once daily for 10 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F175820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F175821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;40 mL/minute: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;40 mL/minute (or patients on hemodialysis/CAPD): 160 mg once daily (administer dose following hemodialysis).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F175822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F175792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Factive&reg;: 320 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F175779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152723.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152723.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F175795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food, milk, or calcium supplements. Gemifloxacin should be taken 3 hours before or 2 hours after supplements (including multivitamins) containing iron, zinc, or magnesium.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F175794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute exacerbation of chronic bronchitis; treatment of community-acquired pneumonia (CAP), including pneumonia caused by multidrug-resistant strains of",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (MDRSP)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F175833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute sinusitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F175835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (4%), dizziness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (5%), nausea (4%), abdominal pain (2%), vomiting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia/neutrophilia (1%), platelets increased (1%), thrombocythemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (1% to 4%), GGT increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, alkaline phosphatase increased, anaphylactic reaction, anemia, anorexia, arthralgia, back pain, bilirubin increased, BUN increased, constipation, cramps (leg), dermatitis, dyspepsia, dyspnea, eczema, eosinophilia, erythema multiforme, facial edema, fatigue, flatulence, flushing, fungal infection, gastritis, gastroenteritis, genital moniliasis, granulocytopenia, hematocrit decreased/increased, hemoglobin decreased/increased, hemorrhage, hot flashes, hyperglycemia, hyper-/hypocalcemia, hyper-/hypokalemia, hyper-/hyponatremia, hypoalbuminemia, INR increased, insomnia, intracranial pressure increased, leukopenia, moniliasis, myalgia, myasthenia gravis exacerbation, nervousness, pain, pharyngitis, photosensitivity, pneumonia, pruritus, pseudomembranous colitis, pseudotumor cerebri, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, retinal hemorrhage, serum creatinine increased, skin exfoliation, somnolence, supraventricular tachycardia, syncope, taste perversion, tendonitis, tendon rupture, thrombocytopenia, TIA, tremor, urticaria, vaginitis, vertigo, vision abnormal, weakness, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Important adverse effects reported with other agents in this drug class include (not reported for gemifloxacin): Allergic reactions, CNS stimulation,  hepatic necrosis/failure, hepatitis, hypersensitivity, jaundice, pancytopenia, peripheral neuropathy, pneumonitis (eosinophilic), seizure,  sensorimotor-axonal neuropathy (paresthesia, hypoesthesias, dysesthesias, weakness), serum sickness, severe dermatologic reactions (toxic epidermal necrolysis, Stevens-Johnson syndrome), thrombotic thrombocytopenia purpura, torsade de pointes, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F175798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gemifloxacin, other fluoroquinolones, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F175782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Fluoroquinolones may prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval; avoid use in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, uncorrected hypokalemia, hypomagnesemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Tremor, restlessness, confusion, and very rarely hallucinations, increased intracranial pressure (including pseudotumor cerebri) or seizures may occur; use with caution in patients with known or suspected CNS disorder. Discontinue in patients who experience significant CNS adverse effects (eg, dizziness, hallucinations, suicidal ideations or actions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as s systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. May cause maculopapular rash, usually 8-10 days after treatment initiation; risk factors may include age &lt;40 years, female gender (including postmenopausal women on HRT), and treatment duration &gt;7 days. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: The use of quinolones has been linked to peripheral neuropathy (rare); discontinue if symptoms of sensory or sensorimotor neuropathy occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions. Discontinue use if photosensitivity occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tendon inflammation/rupture:",
"     <b>",
"      [U.S. Boxed Warning]: There have been reports of tendon inflammation and/or rupture with quinolone antibiotics; risk may be increased with concurrent corticosteroids, organ transplant recipients, and in patients &gt;60 years of age.",
"     </b>",
"     Rupture of the Achilles tendon sometimes requiring surgical repair has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps) have also been reported. Strenuous physical activity may be an independent risk factor for tendonitis. Discontinue at first sign of tendon inflammation or pain. May occur even after discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with significant bradycardia or acute myocardial ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis:",
"     <b>",
"      [U.S. Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis.",
"     </b>",
"     Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported; avoid use in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in renal impairment; dosage adjustment required for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;40 mL/minute. May increase risk of tendon rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in individuals at risk of seizures (CNS disorders or concurrent therapy with medications which may lower seizure threshold). Potential for seizures, although very rare, may be increased with concomitant NSAID therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Adverse effects (eg, tendon rupture, QT changes) may be increased in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F175786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Quinolone Antibiotics may enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the serum concentration of Quinolone Antibiotics. Quinolone Antibiotics may decrease the serum concentration of Didanosine. Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolone Antibiotics. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Quinolone Antibiotics may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the excretion of Gemifloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Quinolone Antibiotics. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the absorption of Quinolone Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Quinolone Antibiotics. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Quinolone Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Quinolone Antibiotics may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Quinolone Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F175812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid dong quai, St John's wort (may also cause photosensitization).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F175788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F175800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies gemifloxacin as pregnancy category C. Quinolone exposure during human pregnancy has been reported with other agents (see Ciprofloxacin [Systemic], Ofloxacin [Systemic], and Norfloxacin [Systemic] monographs). To date, no specific teratogenic effect or increased pregnancy risk has been identified; however, because of concerns of cartilage damage in immature animals exposed to quinolones and the limited gemifloxacin specific data, gemifloxacin should only be used during pregnancy if a safer option is not available.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F175826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F175801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if gemifloxacin is excreted in breast milk. Breast-feeding is not recommended by the manufacturer. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F175802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May take tablets with or without food, milk, or calcium supplements. Gemifloxacin should be taken 3 hours before or 2 hours after supplements (including multivitamins) containing iron, zinc, or magnesium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6487440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Factive Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     320 mg (5): $239.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F175790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     WBC, signs/symptoms of infection, renal function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Factive (CL, KP, TW, ZA);",
"     </li>",
"     <li>",
"      Gemone (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F175781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gemifloxacin is a DNA gyrase inhibitor and also inhibits topoisomerase IV. DNA gyrase (topoisomerase IV) is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; bactericidal",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F175797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 4.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~60% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (minor); forms metabolites (CYP isoenzymes are not involved)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~71%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 7 hours (range 4-12 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 0.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (61%); urine (36%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Calvo A, Gimenez MJ, Alou L, et al, &ldquo;",
"      <i>",
"       Ex Vivo",
"      </i>",
"      Serum Activity (Killing Rates) After Gemifloxacin 320 mg Versus Trovafloxacin 200 mg Single Doses Against Ciprofloxacin-Susceptible and -Resistant",
"      <i>",
"       Streptococcus pneumoniae",
"      </i>",
"      ,\"",
"      <i>",
"       Int J Antimicrob Agents",
"      </i>",
"      , 2002, 20(2):144-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/12297365/pubmed\" id=\"12297365\" target=\"_blank\">",
"        12297365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedrich LV and Dougherty R, &ldquo;Fatal Hypoglycemia Associated With Levofloxacin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(12):1807-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/15585448/pubmed\" id=\"15585448\" target=\"_blank\">",
"        15585448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frothingham R, &ldquo;Glucose Homeostasis Abnormalities Associated With Use of Gatifloxacin,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(9):1269-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/16206101/pubmed\" id=\"16206101\" target=\"_blank\">",
"        16206101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gavin JR 3rd, Kubin R, Choudhri S, et al, &ldquo;Moxifloxacin and Glucose Homeostasis: A Pooled-Analysis of the Evidence From Clinical and Postmarketing Studies,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2004, 27(9):671-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/15230648/pubmed\" id=\"15230648\" target=\"_blank\">",
"        15230648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graumlich JF, Habis S, Avelino RR, et al, &ldquo;Hypoglycemia in Inpatients After Gatifloxacin or Levofloxacin Therapy: Nested Case-Control Study,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(10):1296-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/16185172/pubmed\" id=\"16185172\" target=\"_blank\">",
"        16185172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khaliq Y and Zhanel GG, &ldquo;Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(11):1404-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/12766835/pubmed\" id=\"12766835\" target=\"_blank\">",
"        12766835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kutlin A, Roblin PM, and Hammerschlag MR, &ldquo;Effect of Gemifloxacin on Viability of",
"      <i>",
"       Chlamydia pneumoniae",
"      </i>",
"      (",
"      <i>",
"       Chlamydophila pneumoniae",
"      </i>",
"      ) in an",
"      <i>",
"       In Vitro",
"      </i>",
"      Continuous Infection Model,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2002, 49(5):763-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/12003969/pubmed\" id=\"12003969\" target=\"_blank\">",
"        12003969",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lawrence KR, Adra M, and Keir C, &ldquo;Hypoglycemia-Induced Anoxic Brain Injury Possibly Associated With Levofloxacin,&rdquo;",
"      <i>",
"       J Infect",
"      </i>",
"      , 2006, 52(6):e177-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/16269178/pubmed\" id=\"16269178\" target=\"_blank\">",
"        16269178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lode H, File TM Jr, Mandell L, et al, &ldquo;Oral Gemifloxacin Versus Sequential Therapy With Intravenous Ceftriaxone/Oral Cefuroxime With or Without a Macrolide in the Treatment of Patients Hospitalized With Community-Acquired Pneumonia: A Randomized, Open-Label, Multicenter Study of Clinical Efficacy and Tolerability. 185 Gemifloxacin Study Group,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2002, 24(11):1915-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/12501883/pubmed\" id=\"12501883\" target=\"_blank\">",
"        12501883",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malone RS, Fish DN, Abraham E, et al, &ldquo;Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2001, 45(10):2949-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/11557500/pubmed\" id=\"11557500\" target=\"_blank\">",
"        11557500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al, &ldquo;Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 44 (Suppl 2):27-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/17278083/pubmed\" id=\"17278083\" target=\"_blank\">",
"        17278083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohr JF, McKinnon PS, Peymann PJ, et al, &ldquo;A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(10):1303-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/16185173/pubmed\" id=\"16185173\" target=\"_blank\">",
"        16185173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Park-Wyllie LY, Juurlink DN, Kopp A, et al, &ldquo;Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(13):1352-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/16510739/pubmed\" id=\"16510739\" target=\"_blank\">",
"        16510739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Szarfman A, Chen M, and Blum MD, &ldquo;More on Fluoroquinolone Antibiotics and Tendon Rupture,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(3):193.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang S and Rizvi AA, &ldquo;Levofloxacin-Induced Hypoglycemia in a Nondiabetic Patient,&rdquo;",
"      <i>",
"       Am J Med Sci",
"      </i>",
"      , 2006, 331(6):334-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/16775443/pubmed\" id=\"16775443\" target=\"_blank\">",
"        16775443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson R, Langan C, Ball P, et al, &ldquo;Oral Gemifloxacin Once Daily for 5 Days Compared With Sequential Therapy With I.V. Ceftriaxone/Oral Cefuroxime (Maximum of 10 Days) in the Treatment of Hospitalized Patients With Acute Exacerbations of Chronic Bronchitis. Gemifloxacin 207 Clinical Study Group,&rdquo;",
"      <i>",
"       Respir Med",
"      </i>",
"      , 2003, 97(3):242-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12231/abstract-text/12645831/pubmed\" id=\"12645831\" target=\"_blank\">",
"        12645831",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8760 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-287B6DBA01-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12231=[""].join("\n");
var outline_f11_60_12231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6758349\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175816\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4799816\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175837\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175819\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175820\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175821\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175822\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175792\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175779\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874781\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175795\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175794\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175833\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175835\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175798\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175782\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299394\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175786\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175812\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175788\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175800\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175826\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175801\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175802\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6487440\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175790\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038646\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175781\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175797\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8760\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8760|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/19/22837?source=related_link\">",
"      Gemifloxacin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_60_12232="Prenatal management of neonatal alloimmune thrombocytopenia";
var content_f11_60_12232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal management of neonatal alloimmune thrombocytopenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/60/12232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/60/12232/contributors\">",
"     Michael J Paidas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/60/12232/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/60/12232/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/60/12232/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/60/12232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/60/12232/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/60/12232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal alloimmune thrombocytopenia (NAIT) refers to a disorder in which fetal platelets contain an antigen inherited from the father that the mother lacks. These antibodies cross the placenta and bind to the fetal platelets. Clearance of the antibody-coated platelets results in",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    thrombocytopenia.",
"   </p>",
"   <p>",
"    Antibodies directed against platelet antigen HPA-1a (formerly called PLA-1) account for more than 80 percent of NAIT in Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 98 percent of Caucasians express HPA-1a and about 2 percent of women are HPA-1a negative (HPA-1b homozygotes). Immunoglobulin G (IgG) antibodies (anti HPA-1a) are found in about 10 percent of HPA-1a negative pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The HPA-5b antigen (formerly the Br antigen) is the second most common platelet antigen causing NAIT in Caucasians. In Asians, the HPA-4 system (formerly called Pen or Yuk) is the most frequent cause of NAIT. More than a dozen other platelet antigens have been associated with NAIT. The prevalence of these antigens varies among different ethnic groups; some antigens are quite rare [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of NAIT differs depending on the antigen involved; HPA-1a causes severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/1\">",
"     1",
"    </a>",
"    ]. Other factors, such as HLA type, can modulate severity of disease in offspring. Vascular endothelial dysfunction has also been implicated in the pathogenesis of NAIT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H7#H7\">",
"     \"Neonatal thrombocytopenia\", section on 'Neonatal alloimmune thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mother of a",
"    <span class=\"nowrap\">",
"     fetus/newborn",
"    </span>",
"    with NAIT is asymptomatic.",
"   </p>",
"   <p>",
"    In early pregnancy, in mouse models, maternal antiplatelet antibodies to anti-GPIb&alpha; [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/6\">",
"     6",
"    </a>",
"    ], anti-beta3 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/7\">",
"     7",
"    </a>",
"    ] have been associated with a high risk of miscarriage, which could be prevented by maternal administration of intravenous IgG [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] or a monoclonal antibody specific to the Fc receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/6\">",
"     6",
"    </a>",
"    ]. In one of these models [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/6\">",
"     6",
"    </a>",
"    ], the mechanism for pregnancy loss was severely impaired placental function. Anecdotal reports suggest an increased risk of miscarriage in affected women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/8\">",
"     8",
"    </a>",
"    ], but a possible association in humans has not been studied systematically.",
"   </p>",
"   <p>",
"    Later in pregnancy, the spectrum of disease in the",
"    <span class=\"nowrap\">",
"     fetus/newborn",
"    </span>",
"    ranges from asymptomatic to mild thrombocytopenia with or without petechiae and ecchymoses to severe thrombocytopenia associated with spontaneous fetal or neonatal intracranial hemorrhage. Intracranial hemorrhage is responsible for most of the morbidity and mortality of this condition. It occurs in 7 to 26 percent of cases, and up to 75 percent of these occur antenatally as early as the mid second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/1,9-11\">",
"     1,9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to Rh alloimmunization, NAIT often develops in the first pregnancy of an at-risk couple and can cause intracranial hemorrhage in the first affected pregnancy. Thrombocytopenia may worsen as the gestation progresses; the platelet count can fall by more than 10 x",
"    <span class=\"nowrap\">",
"     1000/mL",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    per week [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With each subsequent affected pregnancy, thrombocytopenia tends to occur earlier in gestation and tends to be more severe. A history of antenatal intracranial hemorrhage in a sibling is predictive of early-onset, more severe disease in the subsequent child.",
"   </p>",
"   <p>",
"    NAIT should be suspected whenever a fetal intracranial hemorrhage is observed sonographically or neonatal thrombocytopenia is noted. The diagnosis is made in thrombocytopenic infants when maternal and paternal platelet typing reveals the father has a platelet antigen that the mother lacks and the mother has detectable antibodies to that antigen.",
"   </p>",
"   <p>",
"    Most cases will involve a mother who is HPA",
"    <span class=\"nowrap\">",
"     1b/1b",
"    </span>",
"    with anti-HPA-1a antibodies and a father who is HPA",
"    <span class=\"nowrap\">",
"     1a/1a",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     1a/1b.",
"    </span>",
"    Approximately 75 percent of Caucasian males are homozygous for the HPA 1a antigen. In addition to the HPA-1a and b, 4 a and b, and 5 a and b, reference laboratories test for a variety of less common platelet antigens, but cannot test for every platelet antigen. Uncommon platelet antigens can be difficult to identify. Testing maternal serum against paternal platelets helps to detect these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/12\">",
"     12",
"    </a>",
"    ]. Unlike Rh alloimmunization, maternal anti-platelet antibody titers are",
"    <strong>",
"     NOT",
"    </strong>",
"    predictive of the degree of fetal thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H7#H7\">",
"     \"Neonatal thrombocytopenia\", section on 'Neonatal alloimmune thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRENATAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Women with no personal or family history of NAIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet typing, specifically identifying women who do not carry the most common antigen triggering NAIT, ie HPA-1a, is not a routine prenatal screening test. Such screening would detect virtually 100 percent of pregnancies at risk of NAIT, while about 15 percent of cases are currently detected when screening only pregnancies with risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening has generally not been shown to be cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], but this is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/2,16,17\">",
"     2,16,17",
"    </a>",
"    ]. Furthermore, there is no consensus as to the optimal management of pregnancies that screen positive. A prospective epidemiologic study of screening estimated that it would cost approximately $100,000 to detect a severe case of NAIT and approximately 2 million dollars to prevent a case of intracranial hemorrhage, assuming that early detection allowed successful intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Personal or family history suggestive of NAIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest maternal platelet antigen typing if a maternal sister had a pregnancy complicated by NAIT. We also suggest maternal platelet antigen typing when the mother or her sister have an obstetrical history suggestive of this diagnosis (eg, fetal death due to intracranial hemorrhage, neonatal thrombocytopenia of undetermined etiology, or in all cases of neonatal thrombocytopenia of &lt;50 x",
"    <span class=\"nowrap\">",
"     1000/mL",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    regardless of etiology). Typically, maternal and paternal human platelet antigen testing are performed simultaneously, looking for a potential incompatibility for the",
"    <span class=\"nowrap\">",
"     HPA-1a/b",
"    </span>",
"    antigen system, but testing can be performed for other rarer platelet alloantigens.",
"   </p>",
"   <p>",
"    In addition to determining whether a platelet antigen incompatibility exists in the couple, screening the maternal serum for platelet antibodies must be performed to determine whether the mother demonstrates specific antibodies directed against the antigen missing from her platelets, but present on the father&rsquo;s platelets. Reference laboratories may vary in the number of platelet alloantigens screened. Often, during the maternal serum evaluation for platelet antibodies, antibodies against human leukocyte antigens (HLA) or ABO antigens, will be identified. These antibodies are not generally thought to cause NAIT, although rarely",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    thrombocytopenia has been identified only in the presence of HLA Class I antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Serial evaluation for HPA antibodies in each trimester is suggested if there is a potential HPA incompatibility in the couple, since specific HPA antibodies may appear later in the pregnancy, due to an anamnestic response.",
"   </p>",
"   <p>",
"    A commonly employed reference laboratory test is a crossmatch test between maternal serum and paternal platelet glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    (GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa),",
"    </span>",
"    the site of most of the significant HPA antigens involved with NAIT. This test will not detect antibodies directed at rare polymorphisms not located on paternal",
"    <span class=\"nowrap\">",
"     IIb/GPa",
"    </span>",
"    structures. Another common test is the modified antigen capture elisa (MACE), which is a two-step procedure that screens for the presence of antibodies in maternal serum directed against paternal platelet glycoprotein complexes.",
"   </p>",
"   <p>",
"    A HPA screening study including greater than 24,000 consecutive pregnancies found 2.5 percent of women were homozygous for HPA-1b and 12 percent of these women had anti-HPA-1a antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/21\">",
"     21",
"    </a>",
"    ]. All but one of the antibody producers was HLA DRB3 0101 positive. The absence of HLA DRB3 0101 had a negative predictive value of 99.6 percent in predicting alloimmunization, while its presence had a positive predictive value of only 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/21\">",
"     21",
"    </a>",
"    ]. Screening the mother for DRB3 0101 can be useful in select circumstances. As an example, if she has a DRB3 0101 positive sister who had an affected child with NAIT, screening for the presence of DRB3 0101 could be performed in the patient to determine the likelihood of developing an HPA-1a antibody response in the index pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pregnancies at-risk of NAIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When maternal and paternal platelet typing document a risk of NAIT, paternal platelet antigen genotyping should be obtained to determine the fetus's risk of being affected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/22\">",
"     22",
"    </a>",
"    ]. As an example, if the affected proband has NAIT due to HPA-1a, the maternal genotype is typically HPA",
"    <span class=\"nowrap\">",
"     1b/1b.",
"    </span>",
"    Approximately 25 percent of fathers will be heterozygous HPA",
"    <span class=\"nowrap\">",
"     1a/1b,",
"    </span>",
"    and 50 percent of their progeny will be also be HPA",
"    <span class=\"nowrap\">",
"     1a/1b",
"    </span>",
"    and at-risk of NAIT. The remaining 75 percent of fathers will be homozygous HPA",
"    <span class=\"nowrap\">",
"     1a/1a,",
"    </span>",
"    and 100 percent of their progeny will be HPA",
"    <span class=\"nowrap\">",
"     1a/1b",
"    </span>",
"    and at-risk. Therefore, on average, after the index case, over 85 percent of the couple's subsequent fetuses will carry the offending platelet antigen and be at-risk for NAIT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PRENATAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fetal platelet typing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the father is heterozygous HPA",
"    <span class=\"nowrap\">",
"     1a/1b,",
"    </span>",
"    the fetal HPA status can be determined by typing fetal DNA for platelet antigens using polymerase chain reaction (PCR). Fetal DNA from cells obtained by chorionic villous sampling or amniocentesis may be used for typing; fetal blood is not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Of the two procedures, amniocentesis is preferred since theoretically chorionic villus sampling could be associated with exacerbation of maternal sensitization in cases of affected fetuses.",
"   </p>",
"   <p>",
"    A test for noninvasive fetal genotyping using cell-free fetal DNA in maternal blood is not commercially available, but is being studied [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of any intervention, thrombocytopenia in the second affected child is always as or more severe than in the previous infant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/1,26\">",
"     1,26",
"    </a>",
"    ]. As discussed above, intracranial hemorrhage is responsible for most of the morbidity and mortality of this condition, occurs in 7 to 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/1,9\">",
"     1,9",
"    </a>",
"    ], and up to 75 percent of these occur antenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The high occurrence of in utero bleeding is the basis for initiating treatment to raise the fetal platelet count antenatally, rather than waiting until birth and treating the neonate. However, there are insufficient data from randomized trials to determine the optimal antenatal management of alloimmune thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These pregnancies should be managed by a specialist in maternal-fetal medicine. Fetuses at highest risk for intracranial hemorrhage are those in which a fetal intracranial hemorrhage occurred in a previous affected sibling. The earlier the intracranial hemorrhage occurred in the previous sibling, the greater the risk for intracranial hemorrhage in the currently affected fetus. The most widely accepted prevention strategy in the United States is weekly maternal antenatal administration of intravenous gamma globulin (IVIG), ranging between 1",
"    <span class=\"nowrap\">",
"     gram/kg/week",
"    </span>",
"    to 2",
"    <span class=\"nowrap\">",
"     gram/kg/week",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Therapy has been initiated as early as 12 weeks of gestation in pregnancies in which a previous intracranial hemorrhage occurred, with good perinatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/29\">",
"     29",
"    </a>",
"    ]. Although use of glucocorticoids in pregnant women has been associated with an increased risk of preterm premature rupture of membranes, this has not been described in the literature of pregnancies complicated by NAIT.",
"   </p>",
"   <p>",
"    Prospective studies have demonstrated that IVIG is effective in reducing the risk of intracranial hemorrhage when compared to prior untreated pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/1,29,31-33\">",
"     1,29,31-33",
"    </a>",
"    ]. A review of studies employing IVIG found that only 11 of 411 (2.7 percent) fetuses treated with IVIG developed an intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/34\">",
"     34",
"    </a>",
"    ]. &nbsp;Long-term follow-up of surviving offspring after antenatal treatment of NAIT with IVIG has not revealed adverse effects on general health or neurodevelopmental outcome, but these data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. One study showed improved neurodevelopment outcomes in the treated sibling, despite being born at an earlier gestational age and lower birthweight [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is still no consensus on the optimal protocol for managing IVIG after it is begun.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210684825\">",
"    <span class=\"h2\">",
"     Platelet transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial fetal platelet transfusions are another treatment option. This approach has fallen out of favor because of the risk of fetal morbidity from repeated invasive procedures and issues regarding obtaining and transfusing appropriate platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/37\">",
"     37",
"    </a>",
"    ]. It is used as a last resort if medical therapy is ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Monitoring fetal platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cordocentesis to determine the fetal platelet count has been used in managing pregnancies complicated by NAIT, but this approach is being minimized or avoided due to the significant procedure related risks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/38\">",
"     38",
"    </a>",
"    ]. Cordocentesis has often been performed prior to initial IVIG therapy, after several weeks of IVIG therapy to assess the response, and prior to delivery to determine whether vaginal delivery should be allowed (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Delivery'",
"    </a>",
"    below). Knowledge of the platelet count does allow the clinician to avoid use of IVIG, which is costly, when the fetus does not have severe thrombocytopenia.",
"   </p>",
"   <p>",
"    If cordocentesis is used in managing NAIT, it should only be performed by experienced maternal fetal medicine specialists. Compatible platelets should be available for immediate direct fetal transfusion if the platelet count is extremely low (&lt;50 x",
"    <span class=\"nowrap\">",
"     1000/mL",
"     <sup>",
"      3",
"     </sup>",
"     ).",
"    </span>",
"    In the past, maternally derived platelets were used, but this practice is no longer routinely recommended. Although there is no absolute threshold for platelet transfusion, we suggest keeping the platelet count above 50 x",
"    <span class=\"nowrap\">",
"     1000/mL",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    to prevent bleeding from the umbilical cord during FBS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36819?source=see_link\">",
"     \"Intrauterine fetal transfusion of platelets\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"   </p>",
"   <p>",
"    Some experts have advocated omitting all cordocentesis and treating pregnancies at risk with IVIG empirically, given the high recurrence rate of NAIT and the risks of cordocentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/3,26,35,39-41\">",
"     3,26,35,39-41",
"    </a>",
"    ]. These two approaches, empiric therapy versus therapy based upon fetal platelet count, have not been compared in randomized trials. A decision analysis concluded that empiric therapy should increase the rate of live births and improve overall quality of life, and at an acceptable increased cost [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach is to minimize the number of invasive procedures by eliminating the initial cordocentesis for determining the fetal platelet count prior to therapy. The initial cordocentesis, at 20 weeks of gestation, may be the most risky since the fetus has not been treated. There is an approximately 1 percent risk of fetal loss from cordocentesis in general and this risk is substantially higher in NAIT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/43\">",
"     43",
"    </a>",
"    ], up to 8 percent per pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/37\">",
"     37",
"    </a>",
"    ], due to the higher risk of exsanguination from the cord puncture site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prospective study including 33 patients proposed a stratified approach that tailored intervention to the timing of the sibling&rsquo;s intracranial hemorrhage and minimized the use of fetal blood sampling, given its high morbidity in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/29\">",
"     29",
"    </a>",
"    ]. Based on their experience with many affected pregnancies, they suggested initiating treatment at 12 weeks with intravenous immunoglobulin 1 or 2",
"    <span class=\"nowrap\">",
"     grams/kg/wk,",
"    </span>",
"    adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or increasing the immunoglobulin dose at 20 to 24 weeks, performing cordocentesis at 32 weeks, and then deciding upon further management based on the platelet count at cordocentesis. Since successful IVIG therapy increases the platelet count in affected fetuses, this approach reduces both the number of cordocentesis procedures and the likelihood of severe thrombocytopenia at the time of cordocentesis, thereby lowering the risk of procedure-related fetal bleeding, as well as other complications. Patients who fail to achieve adequate platelet counts with the initial drug regimen (IVIG 1 to 2",
"    <span class=\"nowrap\">",
"     grams/kg/week",
"    </span>",
"    with or without prednisone 1",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    can still be identified before delivery, and additional interventions undertaken, including increasing the IVIG dose, adding prednisone, in utero platelet transfusion, or delivery. These authors defined an adequate response as a platelet increase of &gt;10 x",
"    <span class=\"nowrap\">",
"     1000/mL",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    compared with the first cordocentesis (if performed) or a platelet count &gt;30 x",
"    <span class=\"nowrap\">",
"     1000/mL",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most experts suggest liberal use of cesarean delivery with consideration of vaginal birth only if the fetal platelet count is greater than 100 x",
"    <span class=\"nowrap\">",
"     1000/mL",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    prior to delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/30\">",
"     30",
"    </a>",
"    ]. However, there is no consensus on criteria for selecting fetuses at low risk of complications after vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal in timing delivery should be to minimize prematurity risks, as well as hemorrhagic risks. There is a trend toward earlier delivery with severe disease, and later delivery with milder forms of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/40\">",
"     40",
"    </a>",
"    ]. We suggest confirmation of lung maturity, if possible, prior to scheduling deliveries before 37 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recombinant, high-affinity human platelet antibody has been developed that blocks binding of maternal HPA-1a specific antibodies to fetal HPA-1b platelets. In a murine model, use of this specific blocking antibody prevented platelet destruction in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/45\">",
"     45",
"    </a>",
"    ]. This advance represents a promising approach that may eventually lead to clinical trials for the treatment of alloimmune thrombocytopenia.",
"   </p>",
"   <p>",
"    Another promising approach in the treatment of alloimmune thrombocytopenia involves targeting a specific receptor, FcRn, which is important for the transport of platelet IgG from the mother to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/46\">",
"     46",
"    </a>",
"    ]. In a murine model of alloimmune thrombocytopenia, antenatal administration of FcRn monoclonal antibodies was associated with increased birth platelet counts, suggesting that modulation of the interaction of antiplatelet IgG with FcRn monoclonal antibodies might represent a new therapeutic target for this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12232/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MATERNAL RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are potential maternal risks associated with treatment of NAIT. Side effects of steroid administration include osteoporosis, impaired glucose tolerance and gestational diabetes, depressed immunity, mood swings, and gastrointestinal irritation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Side effects of IVIG, a blood product, include a local reaction at the administration site, fever, rash, altered immunity, and transmission of infectious agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal strategy for prevention and treatment of neonatal alloimmune thrombocytopenia is controversial. The progress made in the prevention and treatment of this disease has occurred as a result of clinical trials dedicated to determining optimum management strategies. The use of fetal blood sampling, with its associated risks, can be minimized and pregnancies at risk of NAIT can be stratified as low or high risk, so that management can be tailored according to risk of in utero intracranial hemorrhage. Because of the potential serious consequences of this rare disorder, these patients should be cared for by maternal fetal medicine specialists with expertise and familiarity with available treatment options.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonatal alloimmune thrombocytopenia (NAIT) is a disorder in which fetal platelets contain an antigen inherited from the father that the mother lacks. The mother then develops antibodies against this paternal antigen and these antibodies cross the placenta and bind to the fetal platelets. Clearance of the antibody-coated platelets results in",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      thrombocytopenia. Antibodies to HPA 1a are the most common cause of NAIT. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NAIT can occur in a woman's first pregnancy. Intracranial hemorrhage, which may occur antenatally, is responsible for most of the morbidity and mortality of this condition. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NAIT should be suspected whenever a fetal intracranial hemorrhage is observed sonographically or neonatal thrombocytopenia is noted. The diagnosis is made in thrombocytopenic infants when maternal and paternal platelet typing reveals the father has a platelet antigen that the mother lacks and the mother has detectable antibodies to this antigen. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening all pregnant women to identify those who are at risk of NAIT due to maternal-fetal HPA 1a discordancy is costly, and the optimal management of these women is unknown. We suggest not routinely screening pregnant women for HPA 1a (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We perform maternal and paternal platelet antigen typing, as well as maternal human anti-platelet antibody evaluation when the woman or her sister has an obstetrical history suggestive of this diagnosis (eg, fetal death due to intracranial hemorrhage, neonatal thrombocytopenia of undetermined etiology). We perform paternal platelet antigen genotyping if the fetus is at risk of NAIT. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prenatal evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening the mother for DRB3 0101 can be useful in select circumstances. For example, if a patient has a DRB3 0101 positive sister who had an affected child with NAIT, screening for the presence of DRB3 0101 could be performed in the patient to determine the likelihood of developing an HPA-1a antibody response in the index pregnancy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Personal or family history suggestive of NAIT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the father is heterozygous HPA",
"      <span class=\"nowrap\">",
"       1a/1b,",
"      </span>",
"      the fetal HPA status should be determined by typing fetal DNA for platelet antigens by polymerase chain reaction. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Fetal platelet typing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While fetal blood sampling can provide information, such as baseline fetal platelet count and response to therapy, it carries significant risks. The procedure should be reserved for patients who want to attempt a trial of labor and vaginal delivery. An in utero transfusion of platelet concentrate should be performed at the time of fetal blood sampling if it is determined that the fetal platelet count is less than 50 x",
"      <span class=\"nowrap\">",
"       1000/mL",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      in order to avoid exsanguination from the cordocentesis insertion site. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Monitoring fetal platelet count'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest antenatal therapy for women carrying a fetus at risk of recurrent NAIT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Preventive antenatal strategies should be based upon the risk of disease severity. The earlier the intracranial hemorrhage occurred in the previous sibling, the greater the risk for intracranial hemorrhage in the currently affected fetus. In view of the significant risks associated with fetal blood sampling, we prefer treatment algorithms that limit the use of fetal blood sampling. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Drug therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Standard risk",
"      </strong>",
"      &mdash; If the previous affected child had thrombocytopenia without intracranial hemorrhage then appropriate therapies include IVIG 1",
"      <span class=\"nowrap\">",
"       gram/kg/week",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.5",
"      <span class=\"nowrap\">",
"       mg/kg/day,",
"      </span>",
"      or IVIG 2",
"      <span class=\"nowrap\">",
"       gram/kg/week",
"      </span>",
"      initiated at 20 weeks of gestation. At 32 weeks, administer IVIG 2",
"      <span class=\"nowrap\">",
"       gram/kg/week",
"      </span>",
"      and prednisone 0.5",
"      <span class=\"nowrap\">",
"       mg/kg/day.",
"      </span>",
"      Cesarean delivery is recommended at 37 to 38 weeks following amniocentesis documenting fetal lung maturity. Fetal blood sampling is only performed at or after 32 weeks of gestation to determine if the fetal platelet count is adequate (&gt;100 x",
"      <span class=\"nowrap\">",
"       1000/mL",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      for patients who want to undergo a trial of labor and vaginal delivery.",
"     </li>",
"     <li>",
"      <strong>",
"       High risk",
"      </strong>",
"      &mdash; If the previous affected child had an intracranial hemorrhage in the third trimester, a more intense prevention strategy is needed. At 12 weeks of gestation, IVIG is begun at 1",
"      <span class=\"nowrap\">",
"       gram/kg/week.",
"      </span>",
"      At 20 weeks of gestation, either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      is added",
"      <strong>",
"       or",
"      </strong>",
"      the dose of IVIG is increased to 2",
"      <span class=\"nowrap\">",
"       gram/kg/wk.",
"      </span>",
"      At 28 weeks, administer IVIG 2",
"      <span class=\"nowrap\">",
"       gram/kg/week",
"      </span>",
"      and prednisone 0.5",
"      <span class=\"nowrap\">",
"       mg/kg/day.",
"      </span>",
"      Cesarean delivery is recommended at 35 to 36 weeks following amniocentesis documenting fetal lung maturity. Fetal blood sampling is only performed at or after 32 weeks of gestation to determine if the fetal platelet count is adequate (&gt;100 x",
"      <span class=\"nowrap\">",
"       1000/mL",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      for patients want to undergo a trial of labor and vaginal delivery.",
"     </li>",
"     <li>",
"      <strong>",
"       Extremely high risk",
"      </strong>",
"      &mdash; If the previous intracranial hemorrhage occurred in the second trimester, an even more intense prevention strategy is needed. At 12 weeks of gestation, IVIG is begun at 2",
"      <span class=\"nowrap\">",
"       gram/kg/week.",
"      </span>",
"      At 20 weeks of gestation,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      is added. Cesarean delivery is recommended at 35 to 36 weeks following amniocentesis documenting fetal lung maturity. Fetal blood sampling is only performed at or after 32 weeks of gestation to determine if the fetal platelet count is adequate (&gt;100 x",
"      <span class=\"nowrap\">",
"       1000/mL",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      for patients who want to undergo a trial of labor and vaginal delivery.",
"      <br/>",
"      <br/>",
"      Patients presenting in this extremely high risk category are challenging and care should be individualized. The risks of prematurity must be balanced with the risks of in utero hemorrhage, risk of fetal blood sampling, and risk of in utero platelet transfusions.",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest cesarean delivery with consideration of vaginal birth only if the fetal platelet count is greater than 100 x",
"      <span class=\"nowrap\">",
"       1000/mL",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      prior to delivery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Delivery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/1\">",
"      Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N Engl J Med 1997; 337:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/2\">",
"      Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007; 110:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/3\">",
"      Yinon Y, Spira M, Solomon O, et al. Antenatal noninvasive treatment of patients at risk for alloimmune thrombocytopenia without a history of intracranial hemorrhage. Am J Obstet Gynecol 2006; 195:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/4\">",
"      Althaus J, Weir EG, Askin F, et al. Chronic villitis in untreated neonatal alloimmune thrombocytopenia: an etiology for severe early intrauterine growth restriction and the effect of intravenous immunoglobulin therapy. Am J Obstet Gynecol 2005; 193:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/5\">",
"      Kay HH, Hage ML, Kurtzberg J, Dunsmore KP. Alloimmune thrombocytopenia may be associated with systemic disease. Am J Obstet Gynecol 1992; 166:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/6\">",
"      Li C, Piran S, Chen P, et al. The maternal immune response to fetal platelet GPIb&alpha; causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 2011; 121:4537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/7\">",
"      Ni H, Chen P, Spring CM, et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 2006; 107:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/8\">",
"      Murphy MF, Hambley H, Nicolaides K, Waters AH. Severe fetomaternal alloimmune thrombocytopenia presenting with fetal hydrocephalus. Prenat Diagn 1996; 16:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/9\">",
"      Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989; 1:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/10\">",
"      Herman JH, Jumbelic MI, Ancona RJ, Kickler TS. In utero cerebral hemorrhage in alloimmune thrombocytopenia. Am J Pediatr Hematol Oncol 1986; 8:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/11\">",
"      Bussel JB, Berkowitz RL, Lynch L, et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol 1996; 174:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/12\">",
"      Berkowitz RL, Bussel JB, McFarland JG. Alloimmune thrombocytopenia: state of the art 2006. Am J Obstet Gynecol 2006; 195:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/13\">",
"      Tiller H, Killie MK, Skogen B, et al. Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme. BJOG 2009; 116:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/14\">",
"      Turner ML, Bessos H, Fagge T, et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 2005; 45:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/15\">",
"      Durand-Zaleski I, Schlegel N, Blum-Boisgard C, et al. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Immune Thrombocytopenia Working Group. Am J Perinatol 1996; 13:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/16\">",
"      Killie MK, Kjeldsen-Kragh J, Husebekk A, et al. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 2007; 114:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/17\">",
"      Kamphuis MM, Paridaans N, Porcelijn L, et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG 2010; 117:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/18\">",
"      Gramatges MM, Fani P, Nadeau K, et al. Neonatal alloimmune thrombocytopenia and neutropenia associated with maternal human leukocyte antigen antibodies. Pediatr Blood Cancer 2009; 53:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/19\">",
"      del Rosario ML, Fox ER, Kickler TS, Kao KJ. Neonatal alloimmune thrombocytopenia associated with maternal anti-HLA antibody: a case report. J Pediatr Hematol Oncol 1998; 20:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/20\">",
"      Sasaki M, Yagihashi A, Kobayashi D, et al. Neonatal alloimmune thrombocytopenia due to anti-human leukocyte antigen antibody: a case report. Pediatr Hematol Oncol 2001; 18:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/21\">",
"      Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 1998; 92:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/22\">",
"      Lipitz S, Ryan G, Murphy MF, et al. Neonatal alloimmune thrombocytopenia due to anti-P1A1 (anti-HPA-1a): importance of paternal and fetal platelet typing for assessment of fetal risk. Prenat Diagn 1992; 12:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/23\">",
"      Ohto H, Kato K, Tohyama Y, et al. Prenatal determination of human platelet antigen type 4 by DNA amplification of amniotic fluid cells. Transfus Sci 1997; 18:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/24\">",
"      Quintanar A, Jallu V, Legros Y, Kaplan C. Human platelet antigen genotyping using a fluorescent SSCP technique with an automatic sequencer. Br J Haematol 1998; 103:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/25\">",
"      Scheffer PG, Ait Soussan A, Verhagen OJ, et al. Noninvasive fetal genotyping of human platelet antigen-1a. BJOG 2011; 118:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/26\">",
"      Birchall JE, Murphy MF, Kaplan C, et al. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 2003; 122:275.",
"     </a>",
"    </li>",
"    <li>",
"     Rayment, R, Brunskill, S, Stanworth, S, Soothill, P, et al. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev 2005. CD004226.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/28\">",
"      Gaddipati, S, Berkowitz, RL, Lembet, AA, Lapinski, R, McFarland, JG, Bussel, JB. Initial platelet counts predict the response to intravenous gamma globulin therapy in fetuses that are affected by PLA1 incompatibilty. Am J Obstet Gynecol 2006; 107:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/29\">",
"      Bussel JB, Berkowitz RL, Hung C, et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol 2010; 203:135.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/30\">",
"      Pacheco LD, Berkowitz RL, Moise KJ Jr, et al. Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. Obstet Gynecol 2011; 118:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/31\">",
"      Lynch L, Bussel JB, McFarland JG, et al. Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynecol 1992; 80:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/32\">",
"      Bussel JB, Berkowitz RL, McFarland JG, et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988; 319:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/33\">",
"      Berkowitz RL, Kolb EA, McFarland JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 2006; 107:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/34\">",
"      Vinograd CA, Bussel JB. Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. Haematologica 2010; 95:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/35\">",
"      Radder CM, de Haan MJ, Brand A, et al. Follow up of children after antenatal treatment for alloimmune thrombocytopenia. Early Hum Dev 2004; 80:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/36\">",
"      Ward MJ, Pauliny J, Lipper EG, Bussel JB. Long-term effects of fetal and neonatal alloimmune thrombocytopenia and its antenatal treatment on the medical and developmental outcomes of affected children. Am J Perinatol 2006; 23:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/37\">",
"      Overton TG, Duncan KR, Jolly M, et al. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. Am J Obstet Gynecol 2002; 186:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/38\">",
"      Kamphuis MM, Oepkes D. Fetal and neonatal alloimmune thrombocytopenia: prenatal interventions. Prenat Diagn 2011; 31:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/39\">",
"      Kanhai HH, van den Akker ES, Walther FJ, Brand A. Intravenous immunoglobulins without initial and follow-up cordocentesis in alloimmune fetal and neonatal thrombocytopenia at high risk for intracranial hemorrhage. Fetal Diagn Ther 2006; 21:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/40\">",
"      van den Akker ES, Oepkes D, Lopriore E, et al. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG 2007; 114:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/41\">",
"      Mechoulan A, Kaplan C, Muller JY, et al. Fetal alloimmune thrombocytopenia: is less invasive antenatal management safe? J Matern Fetal Neonatal Med 2011; 24:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/42\">",
"      Thung SF, Grobman WA. The cost effectiveness of empiric intravenous immunoglobulin for the antepartum treatment of fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2005; 193:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/43\">",
"      Paidas MJ, Berkowitz RL, Lynch L, et al. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 1995; 172:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/44\">",
"      van den Akker E, Oepkes D, Brand A, Kanhai HH. Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia? BJOG 2006; 113:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/45\">",
"      Ghevaert C, Wilcox DA, Fang J, et al. Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. J Clin Invest 2008; 118:2929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/46\">",
"      Kaplan C. FNAIT: the fetus pleads guilty! Blood 2010; 116:3384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12232/abstract/47\">",
"      Chen P, Li C, Lang S, et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood 2010; 116:3660.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6804 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-0B08567BAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12232=[""].join("\n");
var outline_f11_60_12232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRENATAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Women with no personal or family history of NAIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Personal or family history suggestive of NAIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pregnancies at-risk of NAIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PRENATAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fetal platelet typing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H210684825\">",
"      Platelet transfusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Monitoring fetal platelet count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Future directions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MATERNAL RISKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36819?source=related_link\">",
"      Intrauterine fetal transfusion of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_60_12233="Noninfectious complications following lung transplantation";
var content_f11_60_12233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Noninfectious complications following lung transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/60/12233/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/60/12233/contributors\">",
"     Elbert P Trulock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/60/12233/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/60/12233/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/60/12233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/60/12233/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/60/12233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of complications have been described following lung transplantation, including malignancy, recurrent pulmonary disease, phrenic nerve and diaphragm dysfunction, pneumothorax, and pulmonary embolism.",
"   </p>",
"   <p>",
"    General noninfectious complications of lung transplantation will be reviewed here; other transplant-related complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26121?source=see_link\">",
"     \"Airway complications after lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17194?source=see_link\">",
"     \"Physiologic changes following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid organ transplant recipients have an increased risk for developing malignancy. The cumulative incidence of cancer following kidney and heart transplantation is approximately 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Because lung transplantation is a relatively new procedure, the precise frequency of malignancy after lung transplantation is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the Cincinnati Transplant Tumor Registry, the predominant neoplasms have been lymphomas, skin and lip carcinomas, vulvar or perineal carcinomas, in situ cervical cancer, and Kaposi's sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The risk for cancers that are common in the general population (eg, lung, breast, prostate, colon) has not been increased in transplant recipients.",
"   </p>",
"   <p>",
"    When lung cancer has occurred in patients undergoing lung transplantation, it has typically been described in patients with strong risk factors for lung cancer prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In rare cases, the tumor represents recurrent disease in patients who were transplanted for bronchoalveolar carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. A single-center review of outcomes following lung transplantation identified bronchogenic carcinoma in six of 251 patients (2.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/3\">",
"     3",
"    </a>",
"    ]. All six patients had a history of heavy smoking (mean of nearly 80",
"    <span class=\"nowrap\">",
"     pack/years),",
"    </span>",
"    and five patients had COPD as their indication for transplantation. Given this substrate, the role of immunosuppression in the development of these tumors is not clear. Rapid disease progression was noted in four of the patients, and one- and two-year survival rates were 33 and 17 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diverse lymphoproliferative diseases (including lymphoma) that arise after transplantation are referred to collectively as posttransplantation lymphoproliferative disorders (PTLD). They comprise a morphologically and clonally heterogeneous group closely associated with Epstein-Barr virus (EBV) infection. Three types have been described: polyclonal B cell proliferation with normal cytogenetics; polyclonal B cell proliferation with early malignant transformation; and monoclonal B cell proliferation malignant cytogenetic abnormalities (lymphoma).",
"   </p>",
"   <p>",
"    The pathogenesis and treatment of PTLD are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .) The following discussion is limited to issues specifically related to lung transplant recipients. In these patients, PTLD tends to present at an advanced stage and often involves the transplanted lung. The allograft frequently has single or multiple well-defined nodules, and involvement of other sites, including the central nervous system is common [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/1,2,8-10\">",
"     1,2,8-10",
"    </a>",
"    ]. Localized disease in other organs has also occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased frequency of involvement of the transplanted lung suggests a possible role for the local immune reaction against the graft as a predisposing factor. Consistent with this hypothesis is the following observation in renal and cardiac transplant recipients: Among patients who developed NHL, renal transplant recipients were much more likely to have renal lymphoma (14.2 versus 0.7 percent in heart transplant recipients), while heart transplant recipients were more likely to develop lymphoma in the heart or especially the lungs (17.9 versus 6.8 percent in renal transplant recipients) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of PTLD is markedly increased in transplant recipients who were EBV-seronegative before transplantation and then acquired a primary EBV infection in the posttransplant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Perhaps for this reason, the risk of PTLD is higher in children than in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/17\">",
"     17",
"    </a>",
"    ]. No increased risk has been associated with rejection, dosage of pulse steroids or antilymphocytic agents, patterns of antiviral therapy, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    -based maintenance immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/14,17\">",
"     14,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for PTLD after lung transplantation remains unknown. Regression has followed a reduction in the intensity of maintenance immunosuppression, particularly in early cases, but the risk of rejection is high [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Other interventions have included [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/10,17,19-25\">",
"     10,17,19-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surgical excision",
"     </li>",
"     <li>",
"      Radiation therapy",
"     </li>",
"     <li>",
"      Chemotherapy",
"     </li>",
"     <li>",
"      Extracorporeal photochemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      , interferon alfa, lymphokine-activated killer cells, or anti-B cell monoclonal antibodies (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Retransplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sustained clinical remissions have been achieved in some cases, but overall the prognosis is guarded in lung transplant recipients. Deaths usually result from progression and spread of PTLD, complications of therapy, or bronchiolitis obliterans secondary to chronic rejection. In a report of 20 cases, the one and two year actuarial survival rates after the diagnosis of PTLD were 50 and 19 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/17\">",
"     17",
"    </a>",
"    ]. The role of specific therapy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible efficacy of prophylactic antiviral therapy in lung transplant recipients is uncertain. One center described a reduction in the incidence of PTLD from 3.9 to 0.5 percent with the use of prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    during antilymphocyte antibody administration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/26\">",
"     26",
"    </a>",
"    ]. However, historical controls were used in this study, and these findings must be confirmed before routine anti-EBV prophylaxis can be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RECURRENT PRIMARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of diseases have been reported to recur in the lung allograft, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/27-31\">",
"       27-31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lymphangioleiomyomatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diffuse panbronchiolitis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pulmonary alveolar proteinosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Desquamative interstitial pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pulmonary Langerhans cell histiocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bronchioloalveolar carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/5,40\">",
"       5,40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Idiopathic pulmonary hemosiderosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Giant cell interstitial pneumonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Alpha-1-antitrypsin deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pulmonary veno-occlusive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sarcoidosis in particular has had a high pathologic recurrence rate in some small series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/46\">",
"     46",
"    </a>",
"    ]. It usually is discovered incidentally when noncaseating granulomas are noted on lung biopsy specimens, but these pathologic recurrences have not adversely affected outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/28\">",
"     28",
"    </a>",
"    ]. As an example, one series of 12 patients found posttransplantation recurrence of sarcoidosis in 3, but reported 3- and 5-year survival rates comparable to those of patients transplanted for other diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the history of lung transplantation is brief compared with the natural history of the underlying diseases, it would not be surprising for recurrence of other diseases to be described in the future among long-term surviving patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GRAFT-VERSUS-HOST DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graft-versus-host disease (GVHD) results from an attack by viable donor lymphocytes on lymphoid tissues in an immunosuppressed recipient. This immunologic assault is manifested clinically by dysfunction of the skin, liver, gastrointestinal tract, and bone marrow (",
"    <a class=\"graphic graphic_table graphicRef68233 \" href=\"UTD.htm?8/63/9212\">",
"     table 1",
"    </a>",
"    ). GVHD is common following hematopoietic stem cell transplantation, and is a rare complication of lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=see_link\">",
"     \"Pathogenesis of graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Six cases of GVHD following lung transplantation have been reported in the literature. In these cases, patients generally developed rapidly progressive cholestatic hepatitis, gastroenteritis, and dermatitis. Neutropenia was noted in all four patients reported in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/48\">",
"     48",
"    </a>",
"    ]. The diagnosis is suggested based on clinical findings; however, severe drug reactions may result in a similar presentation. The diagnosis is confirmed by skin biopsy and by chimerism studies on peripheral blood, which quantify the percentage of circulating lymphocytes of donor and recipient origin. Although rare, GVHD in lung transplant recipients appears to have a very high mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PHRENIC NERVE AND DIAPHRAGMATIC DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of diaphragmatic paralysis following lung transplantation has ranged from 3 to 9 percent in retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, this complication may be under-diagnosed, and a frequency of 30 percent was noted in a single prospective study of 27 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/53\">",
"     53",
"    </a>",
"    ]. Phrenic nerve injury is more common following heart-lung transplantation than after lung transplantation; in one retrospective report, more than 40 percent of heart-lung transplant recipients developed this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism is operative injury to the phrenic nerve at the time of the transplant, and no specific risk factors for phrenic nerve injury have been identified. Diaphragmatic dysfunction resulted in longer hospital stays, but did not appear to cause serious long-term sequelae even though there was no evidence of recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=see_link\">",
"     \"Causes and diagnosis of bilateral diaphragmatic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early post-transplantation cardiovascular complications includes include hemodynamic instability, myocardial injury and rhythm disturbances. Some degree of hemodynamic instability is not unusual in the first 24 hours after transplantation, but it usually responds to appropriate management of intravascular volume status and to judicious use of vasopressors or inotropes. Intraoperative coronary artery air embolism, cardiac manipulation during the procedure, post-operative coronary artery embolism of small thrombi from the left atrial pulmonary venous anastomosis, or infarction from pre-existing coronary artery disease can cause myocardial injury, but clinically significant myocardial injury with ventricular dysfunction is uncommon because most of these complications are preventable.",
"   </p>",
"   <p>",
"    Atrial dysrhythmias, primarily flutter and fibrillation, have been reported in approximately 40 percent of recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. In one series, risk factors for post-transplantation atrial fibrillation or flutter included recipient age &ge; 50 years, pre-existing coronary artery disease, diagnosis of idiopathic pulmonary fibrosis, vasopressors therapy and enlarged left atrium on echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/55\">",
"     55",
"    </a>",
"    ]. Atrial fibrillation and flutter usually respond to conventional treatments, including rate control medications, antiarrhythmic drugs like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and cardioversion if indicated, but the dysrhythmias prolong hospitalization and may be associated with increased mortality. In most cases antiarrhythmic drug therapy can be stopped 6 to 12 weeks after transplantation with a low risk of recurrence. Methods to prevent these dysrhythmias after lung transplantation have not been carefully studied.",
"   </p>",
"   <p>",
"    In the long-term, risk factors for cardiovascular disease develop in many lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Among five-year survivors in the Registry of the International Society for Heart and Lung Transplantation, the prevalence of risk factors was very high - systemic hypertension, 86 percent; hyperlipidemia, 47 percent; renal insufficiency, 39 percent; and diabetes mellitus, 31 percent. In a recent single-center follow-up study of 126 recipients without hypertension, hypercholesterolemia, or diabetes mellitus before transplantation, at least one cardiovascular risk factor had developed in 90 percent of the recipients by three years after transplantation. Most of these risk factors are, directly or indirectly, related to the post-transplantation immunosuppressive medications. Thus, to certain extent, these risk factors are unavoidable in many recipients, but they should be controlled as well as possible with the standard modalities of diet, exercise, and drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PLEURAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural complications occurred in 22 percent of 138 patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/58\">",
"     58",
"    </a>",
"    ]. Prolonged (greater than 14 days) postoperative pneumothorax or recurrent pneumothorax accounted for almost one-half of the complications. A variety of other complications were observed, most of which resolved with conservative management. In three of seven cases, empyema was associated with sepsis and death.",
"   </p>",
"   <p>",
"    Pleural effusions are common after lung transplantation, and generally are not problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32103?source=see_link\">",
"     \"The pleura in lung transplantation\"",
"    </a>",
"    .) Increased alveolar capillary permeability and disruption of the pulmonary lymphatics have been postulated as the primary mechanisms, and superimposed allograft rejection contributes in some cases. The fluid is exudative, and is initially similar to pleural fluid after other cardiothoracic operations. The output declines during the first ten days; sequential fluid analysis thereafter should show a falling protein concentration and a rising proportion of lymphocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PULMONARY EMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplant recipients, like other patients undergoing major surgery, are at increased risk of thromboembolism. Pulmonary artery reserve tends to be limited during the recovery phase; as a result, an embolus to the transplanted lung can have serious consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/60\">",
"     60",
"    </a>",
"    ]. Because the clinical picture is frequently complex after lung transplantation and the presentation of thromboembolism is nonspecific, a high index of suspicion is necessary for diagnosis. Standard methods of prophylaxis should be used, but have not been prospectively evaluated in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deep venous thrombosis or pulmonary embolism was documented in 12 percent of patients in one series of 116 lung or heart-lung recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/61\">",
"     61",
"    </a>",
"    ]. Clots were found in both the upper and lower extremities, the former in association with indwelling central venous catheters, and were successfully managed with conventional approaches. Pulmonary embolism was diagnosed in seven patients, and contributed to the death of three despite appropriate treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HYPERAMMONEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case reports have described the development of fatal hyperammonemia following lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], and one series documented hyperammonemia in 6 of 145 lung transplant recipients at a single institution [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/64\">",
"     64",
"    </a>",
"    ]. In this series, hyperammonemia was more common among patients with major gastrointestinal complications, patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    , and patients transplanted for idiopathic pulmonary arterial hypertension. Other proposed explanations for hyperammonemia have included an idiosyncratic reaction to immunosuppressive medications, analgesics, or antibiotics. Impairment of the hepatic enzyme glutamine synthetase appears to play a major role in the development of hyperammonemia, but why this occurs is not well understood.",
"   </p>",
"   <p>",
"    Successful treatment of patients with this disorder has been described with the use of a combination of hemodialysis, bowel decontamination, and the administration of arginine,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/6/32866?source=see_link\">",
"     sodium benzoate",
"    </a>",
"    , and sodium phenylacetate to stimulate alternative pathways of nitrogen excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. However, uncertainty about the etiology and natural history of this complication makes assessment of the effectiveness of these interventions problematic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OTHER COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplant recipients may have a panoply of other medical and surgical problems. Most of these are not unique to lung transplantation, but instead are side effects of the immunosuppressive medications or general medical problems that are aggravated by the posttransplantation regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Prominent problems include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoporosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/67-70\">",
"       67-70",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=see_link\">",
"       \"Osteoporosis after solid organ or stem cell transplantation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic renal failure related in part to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ; this complication is seen in 10 to 15 percent of patients alive three years and approximately 20 percent at six years after transplantation (",
"      <a class=\"graphic graphic_figure graphicRef54972 \" href=\"UTD.htm?35/21/36190\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/71\">",
"       71",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link&amp;anchor=H5#H5\">",
"       \"Cyclosporine and tacrolimus nephrotoxicity\", section on 'Incidence'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/67,72\">",
"       67,72",
"      </a>",
"      ]. The development of hypertension following lung or heart-lung transplantation is also associated with an increased risk of chronic renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/74\">",
"       74",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=see_link\">",
"       \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/75\">",
"       75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Gastroesophageal reflux disease (GERD) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Gastroparesis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypercholesterolemia and hypertriglyceridemia",
"     </li>",
"     <li>",
"      Cholecystitis",
"     </li>",
"     <li>",
"      Diverticulitis",
"     </li>",
"     <li>",
"      Weakness of respiratory and limb muscles [",
"      <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/80-82\">",
"       80-82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulmonary capillaritis is another possible complication of transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/60/12233/abstract/83\">",
"     83",
"    </a>",
"    ]. A retrospective review of 40 cases of biopsy-proven pulmonary capillaritis reported that most patients presented with dyspnea, hypoxemia, an abnormal chest x-ray, and decreased FEV1. Less commonly, patients presented with hemoptysis (25 percent) or fulminant respiratory failure (18 percent). Intravenous corticosteroids resulted in improvement in 43 percent of cases. Sixty-seven percent of patients refractory to corticosteroids responded to plasmapheresis. Five patients (12 percent) died. Most survivors had minimal loss of allograft function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4548012\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Solid organ transplant recipients have an increased risk for developing malignancy. Since the major indications for lung transplantation are emphysema and idiopathic pulmonary fibrosis, diseases associated with an increased risk of lung cancer, single-lung recipients are at increased risk for developing lung cancer in the native lung. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Posttransplantation lymphoproliferative disorders (PTLD) tend to present at an advanced stage in lung transplant recipients and often involve the transplanted lung. The allograft frequently has single or multiple well-defined nodules; involvement of other sites (eg, central nervous system) is common. The risk of PTLD is markedly increased in transplant recipients who are Epstein-Barr virus (EBV)-seronegative before transplantation and then acquire a primary EBV infection in the posttransplant setting. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Posttransplantation lymphoproliferative disorders'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of diseases have been reported to recur in the lung allograft, including sarcoidosis, lymphangioleiomyomatosis, diffuse panbronchiolitis, and pulmonary alveolar proteinosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Recurrent primary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diaphragmatic dysfunction due to phrenic nerve injury is a potential complication of lung transplantation. Diaphragm paralysis should be suspected in patients with postoperative dyspnea, hypoxemia, hypoventilation, atelectasis, hemidiaphragm elevation on an upright chest radiograph, or difficulty weaning from the ventilator postoperatively. The diagnosis of unilateral diaphragmatic paralysis is usually made by fluoroscopic examination of the diaphragm, while bilateral paralysis may be strongly suspected based on the setting, bilateral elevation of the diaphragm, and supine and sitting spirometry. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Phrenic nerve and diaphragmatic dysfunction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12247?source=see_link\">",
"       \"Causes and diagnosis of unilateral diaphragmatic paralysis and eventration\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=see_link\">",
"       \"Causes and diagnosis of bilateral diaphragmatic paralysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=see_link\">",
"       \"Treatment of diaphragmatic paralysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lung transplant recipients, like other patients undergoing major surgery, are at increased risk of deep venous thrombosis and pulmonary embolism. The presentation of pulmonary embolism is nonspecific, so a high index of suspicion is necessary. Standard methods of prophylaxis should be used, but have not been prospectively evaluated in this population. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pulmonary embolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Airway anastomotic complications are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26121?source=see_link\">",
"       \"Airway complications after lung transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/1\">",
"      Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993; 12:S328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/2\">",
"      Penn I. Neoplastic complications of transplantation. Semin Respir Infect 1993; 8:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/3\">",
"      Arcasoy SM, Hersh C, Christie JD, et al. Bronchogenic carcinoma complicating lung transplantation. J Heart Lung Transplant 2001; 20:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/4\">",
"      Yserbyt J, Verleden GM, Dupont LJ, et al. Bronchial carcinoma after lung transplantation: a single-center experience. J Heart Lung Transplant 2012; 31:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/5\">",
"      Garver RI Jr, Zorn GL, Wu X, et al. Recurrence of bronchioloalveolar carcinoma in transplanted lungs. N Engl J Med 1999; 340:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/6\">",
"      de Perrot M, Fischer S, Waddell TK, et al. Management of lung transplant recipients with bronchogenic carcinoma in the native lung. J Heart Lung Transplant 2003; 22:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/7\">",
"      de Perrot M, Chernenko S, Waddell TK, et al. Role of lung transplantation in the treatment of bronchogenic carcinomas for patients with end-stage pulmonary disease. J Clin Oncol 2004; 22:4351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/8\">",
"      Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/9\">",
"      Rappaport DC, Chamberlain DW, Shepherd FA, Hutcheon MA. Lymphoproliferative disorders after lung transplantation: imaging features. Radiology 1998; 206:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/10\">",
"      Reams BD, McAdams HP, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/11\">",
"      Heller T, Drachenberg CB, Orens JB, Fantry GT. Primary posttransplant lymphoproliferative disorder of the gallbladder in a lung transplant patient presenting with acute cholecystitis. Transplantation 2000; 69:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/12\">",
"      Herrmann BW, Sweet SC, Molter DW. Sinonasal posttransplant lymphoproliferative disorder in pediatric lung transplant patients. Otolaryngol Head Neck Surg 2005; 133:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/13\">",
"      Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/14\">",
"      Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-na&iuml;ve lung transplant recipient. Am J Respir Crit Care Med 1996; 154:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/15\">",
"      Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/16\">",
"      Wigle DA, Chaparro C, Humar A, et al. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation 2001; 72:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/17\">",
"      Pham, SM, Keenan, RJ, Kawai, A, et al. Posttransplant lymphoproliferative disease after lung transplantation (abstract). J Heart Lung Transplant 1996; 15:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/18\">",
"      Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/19\">",
"      Paradis IL, Williams P. Infection after lung transplantation. Semin Respir Infect 1993; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/20\">",
"      Garrett TJ, Chadburn A, Barr ML, et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 1993; 72:2782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/21\">",
"      Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/22\">",
"      DeMario MD, Liebowitz DN. Lymphomas in the immunocompromised patient. Semin Oncol 1998; 25:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/23\">",
"      Schoch OD, Boehler A, Speich R, Nestle FO. Extracorporeal photochemotherapy for Epstein-Barr virus-associated lymphoma after lung transplantation. Transplantation 1999; 68:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/24\">",
"      Reynaud-Gaubert M, Stoppa AM, Gaubert J, et al. Anti-CD20 monoclonal antibody therapy in Epstein-Barr Virus-associated B cell lymphoma following lung transplantation. J Heart Lung Transplant 2000; 19:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/25\">",
"      Raj R, Frost AE. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients. J Heart Lung Transplant 2005; 24:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/26\">",
"      Darenkov IA, Marcarelli MA, Basadonna GP, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/27\">",
"      Milman N, Andersen CB, Burton CM, Iversen M. Recurrent sarcoid granulomas in a transplanted lung derive from recipient immune cells. Eur Respir J 2005; 26:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/28\">",
"      Johnson BA, Duncan SR, Ohori NP, et al. Recurrence of sarcoidosis in pulmonary allograft recipients. Am Rev Respir Dis 1993; 148:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/29\">",
"      Yeatman M, McNeil K, Smith JA, et al. Lung Transplantation in patients with systemic diseases: an eleven-year experience at Papworth Hospital. J Heart Lung Transplant 1996; 15:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/30\">",
"      Kazerooni EA, Jackson C, Cascade PN. Sarcoidosis: recurrence of primary disease in transplanted lungs. Radiology 1994; 192:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/31\">",
"      Bj&oslash;rtuft O, Foerster A, Boe J, Geiran O. Single lung transplantation as treatment for end-stage pulmonary sarcoidosis: recurrence of sarcoidosis in two different lung allografts in one patient. J Heart Lung Transplant 1994; 13:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/32\">",
"      Nine JS, Yousem SA, Paradis IL, et al. Lymphangioleiomyomatosis: recurrence after lung transplantation. J Heart Lung Transplant 1994; 13:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/33\">",
"      O'Brien JD, Lium JH, Parosa JF, et al. Lymphangiomyomatosis recurrence in the allograft after single-lung transplantation. Am J Respir Crit Care Med 1995; 151:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/34\">",
"      Baz MA, Kussin PS, Van Trigt P, et al. Recurrence of diffuse panbronchiolitis after lung transplantation. Am J Respir Crit Care Med 1995; 151:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/35\">",
"      Parker LA, Novotny DB. Recurrent alveolar proteinosis following double lung transplantation. Chest 1997; 111:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/36\">",
"      King MB, Jessurun J, Hertz MI. Recurrence of desquamative interstitial pneumonia after lung transplantation. Am J Respir Crit Care Med 1997; 156:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/37\">",
"      Etienne B, Bertocchi M, Gamondes JP, et al. Relapsing pulmonary Langerhans cell histiocytosis after lung transplantation. Am J Respir Crit Care Med 1998; 157:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/38\">",
"      Habib SB, Congleton J, Carr D, et al. Recurrence of recipient Langerhans' cell histiocytosis following bilateral lung transplantation. Thorax 1998; 53:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/39\">",
"      Gabbay E, Dark JH, Ashcroft T, et al. Recurrence of Langerhans' cell granulomatosis following lung transplantation. Thorax 1998; 53:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/40\">",
"      Paloyan EB, Swinnen LJ, Montoya A, et al. Lung transplantation for advanced bronchioloalveolar carcinoma confined to the lungs. Transplantation 2000; 69:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/41\">",
"      Wroblewski BM, Stefanovic CR, McDonough VM, Kidik PJ. The challenges of idiopathic pulmonary hemosiderosis and lung transplantation. Crit Care Nurse 1997; 17:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/42\">",
"      Calabrese F, Giacometti C, Rea F, et al. Recurrence of idiopathic pulmonary hemosiderosis in a young adult patient after bilateral single-lung transplantation. Transplantation 2002; 74:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/43\">",
"      Frost AE, Keller CA, Brown RW, et al. Giant cell interstitial pneumonitis. Disease recurrence in the transplanted lung. Am Rev Respir Dis 1993; 148:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/44\">",
"      Mal H, Guignabert C, Thabut G, et al. Recurrence of pulmonary emphysema in an alpha-1 proteinase inhibitor-deficient lung transplant recipient. Am J Respir Crit Care Med 2004; 170:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/45\">",
"      Izbicki G, Shitrit D, Schechtman I, et al. Recurrence of pulmonary veno-occlusive disease after heart-lung transplantation. J Heart Lung Transplant 2005; 24:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/46\">",
"      Collins J, Hartman MJ, Warner TF, et al. Frequency and CT findings of recurrent disease after lung transplantation. Radiology 2001; 219:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/47\">",
"      Walker S, Mikhail G, Banner N, et al. Medium term results of lung transplantation for end stage pulmonary sarcoidosis. Thorax 1998; 53:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/48\">",
"      Luckraz H, Zagolin M, McNeil K, Wallwork J. Graft-versus-host disease in lung transplantation: 4 case reports and literature review. J Heart Lung Transplant 2003; 22:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/49\">",
"      Pfitzmann R, Hummel M, Grauhan O, et al. Acute graft-versus-host disease after human heart-lung transplantation: a case report. J Thorac Cardiovasc Surg 1997; 114:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/50\">",
"      Chau EM, Lee J, Yew WW, et al. Mediastinal irradiation for graft-versus-host disease in a heart-lung transplant recipient. J Heart Lung Transplant 1997; 16:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/51\">",
"      Maziak DE, Maurer JR, Kesten S. Diaphragmatic paralysis: a complication of lung transplantation. Ann Thorac Surg 1996; 61:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/52\">",
"      Ferdinande P, Bruyninckx F, Van Raemdonck D, et al. Phrenic nerve dysfunction after heart-lung and lung transplantation. J Heart Lung Transplant 2004; 23:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/53\">",
"      Sheridan PH Jr, Cheriyan A, Doud J, et al. Incidence of phrenic neuropathy after isolated lung transplantation. The Loyola University Lung Transplant Group. J Heart Lung Transplant 1995; 14:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/54\">",
"      Lau CL, Patterson GA, Palmer SM. Critical care aspects of lung transplantation. J Intensive Care Med 2004; 19:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/55\">",
"      Nielsen TD, Bahnson T, Davis RD, Palmer SM. Atrial fibrillation after pulmonary transplant. Chest 2004; 126:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/56\">",
"      Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report--2005. J Heart Lung Transplant 2005; 24:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/57\">",
"      Silverborn M, Jeppsson A, M&aring;rtensson G, Nilsson F. New-onset cardiovascular risk factors in lung transplant recipients. J Heart Lung Transplant 2005; 24:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/58\">",
"      Herridge MS, de Hoyos AL, Chaparro C, et al. Pleural complications in lung transplant recipients. J Thorac Cardiovasc Surg 1995; 110:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/59\">",
"      Judson MA, Handy JR, Sahn SA. Pleural effusions following lung transplantation. Time course, characteristics, and clinical implications. Chest 1996; 109:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/60\">",
"      Noda S, Sundt TM 3rd, Lynch JP, et al. Pulmonary embolectomy after single-lung transplantation. Ann Thorac Surg 1997; 64:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/61\">",
"      Kroshus TJ, Kshettry VR, Hertz MI, Bolman RM 3rd. Deep venous thrombosis and pulmonary embolism after lung transplantation. J Thorac Cardiovasc Surg 1995; 110:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/62\">",
"      Lichtenstein GR, Kaiser LR, Tuchman M, et al. Fatal hyperammonemia following orthotopic lung transplantation. Gastroenterology 1997; 112:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/63\">",
"      Tuchman M, Lichtenstein GR, Rajagopal BS, et al. Hepatic glutamine synthetase deficiency in fatal hyperammonemia after lung transplantation. Ann Intern Med 1997; 127:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/64\">",
"      Lichtenstein GR, Yang YX, Nunes FA, et al. Fatal hyperammonemia after orthotopic lung transplantation. Ann Intern Med 2000; 132:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/65\">",
"      Bruno S, Borzio M, Battezzati PM. Interferon-alpha in chronic hepatitis C. Ann Intern Med 1998; 128:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/66\">",
"      Kotloff RM, Ahya VN. Medical complications of lung transplantation. Eur Respir J 2004; 23:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/67\">",
"      Schuurmans MM, Tini GM, Zuercher A, et al. Practical approach to emergencies in lung transplant recipients: how we do it. Respiration 2012; 84:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/68\">",
"      Aris RM, Neuringer IP, Weiner MA, et al. Severe osteoporosis before and after lung transplantation. Chest 1996; 109:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/69\">",
"      Shane E, Papadopoulos A, Staron RB, et al. Bone loss and fracture after lung transplantation. Transplantation 1999; 68:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/70\">",
"      Spira A, Gutierrez C, Chaparro C, et al. Osteoporosis and lung transplantation: a prospective study. Chest 2000; 117:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/71\">",
"      Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/72\">",
"      Morrison RJ, Short HD, Noon GP, Frost AE. Hypertension after lung transplantation. J Heart Lung Transplant 1993; 12:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/73\">",
"      Kunst H, Thompson D, Hodson M. Hypertension as a marker for later development of end-stage renal failure after lung and heart-lung transplantation: a cohort study. J Heart Lung Transplant 2004; 23:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/74\">",
"      Jindal RM. Posttransplant diabetes mellitus--a review. Transplantation 1994; 58:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/75\">",
"      End A, Stift A, Wieselthaler G, et al. Anemia and erythropoietin levels in lung transplant recipients. Transplantation 1995; 60:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/76\">",
"      Young LR, Hadjiliadis D, Davis RD, Palmer SM. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 2003; 124:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/77\">",
"      Davis RD Jr, Lau CL, Eubanks S, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003; 125:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/78\">",
"      Berkowitz N, Schulman LL, McGregor C, Markowitz D. Gastroparesis after lung transplantation. Potential role in postoperative respiratory complications. Chest 1995; 108:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/79\">",
"      Akindipe OA, Faul JL, Vierra MA, et al. The surgical management of severe gastroparesis in heart/lung transplant recipients. Chest 2000; 117:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/80\">",
"      Pantoja JG, Andrade FH, Stoki DS, et al. Respiratory and limb muscle function in lung allograft recipients. Am J Respir Crit Care Med 1999; 160:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/81\">",
"      Krieger AC, Szidon P, Kesten S. Skeletal muscle dysfunction in lung transplantation. J Heart Lung Transplant 2000; 19:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/82\">",
"      Pinet C, Scillia P, Cassart M, et al. Preferential reduction of quadriceps over respiratory muscle strength and bulk after lung transplantation for cystic fibrosis. Thorax 2004; 59:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/60/12233/abstract/83\">",
"      Astor TL, Weill D, Cool C, et al. Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. J Heart Lung Transplant 2005; 24:2091.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4656 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12233=[""].join("\n");
var outline_f11_60_12233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4548012\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RECURRENT PRIMARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GRAFT-VERSUS-HOST DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PHRENIC NERVE AND DIAPHRAGMATIC DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CARDIOVASCULAR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PLEURAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PULMONARY EMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HYPERAMMONEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OTHER COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4548012\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4656\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4656|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/21/36190\" title=\"figure 1\">",
"      Incidence of CKD after nonrenal organ TPL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4656|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/63/9212\" title=\"table 1\">",
"      Grade GVHD by organ system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26121?source=related_link\">",
"      Airway complications after lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=related_link\">",
"      Causes and diagnosis of bilateral diaphragmatic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12247?source=related_link\">",
"      Causes and diagnosis of unilateral diaphragmatic paralysis and eventration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=related_link\">",
"      New onset diabetes after transplant (NODAT) in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=related_link\">",
"      Osteoporosis after solid organ or stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=related_link\">",
"      Pathogenesis of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17194?source=related_link\">",
"      Physiologic changes following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32103?source=related_link\">",
"      The pleura in lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=related_link\">",
"      Treatment of diaphragmatic paralysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_60_12234="Voriconazole: Pediatric drug information";
var content_f11_60_12234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Voriconazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"    see \"Voriconazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/39/33397?source=see_link\">",
"    see \"Voriconazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      VFEND&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      VFEND&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Triazole",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limited data available. Oral, I.V.: 2-4 mg/kg/dose every 12 hours has been reported in five neonates (Frankenbusch, 2006; Kohli, 2008; Santos, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"      see \"Voriconazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2 to &lt;12 years:",
"     <b>",
"      Note:",
"     </b>",
"     Limited information regarding pediatric dosing exists. Dosing below represents small studies and expert opinion; children &le;12 years appear to require higher dosing than adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Aspergillosis, invasive, including disseminated and extrapulmonary infection:",
"     </b>",
"     Duration of therapy should be a minimum of 6-12 weeks or throughout period of immunosuppression (Walsh, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     IDSA Guidelines: 5-7 mg/kg/dose every 12 hours (Walsh, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CDC Opportunistic Infections Guidelines (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Loading dose: 6-8 mg/kg/dose (maximum: 400 mg/dose) every 12 hours for 2 doses on day 1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Maintenance dose: 7 mg/kg/dose (maximum: 200 mg/dose) every 12 hours; change to oral administration when able; duration of therapy (I.V. and oral combined): &ge;12 weeks but should be individualized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Loading dose: 8 mg/kg/dose (maximum: 400 mg/dose) every 12 hours for 2 doses on day 1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance dose: 7 mg/kg/dose (maximum: 200 mg/dose) every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Candidiasis or other serious fungal infection, treatment:",
"     </b>",
"     I.V.: 7-8 mg/kg/dose every 12 hours; dosing based on pharmacokinetic data which demonstrated similar plasma exposure as adults dosed at usual 4 mg/kg twice daily (Pappas, 2009; Walsh, 2010). Simulations predicted an initial I.V. dose of 7 mg/kg every 12 hours would achieve serum trough concentrations &gt;1 mcg/mL in most children up to 12 years of age (Neely, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Aspergillosis, invasive, including disseminated and extrapulmonary infection:",
"     </b>",
"     Duration of therapy should be a minimum of 6-12 weeks or throughout period of immunosuppression (Walsh, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Initial: Loading dose: 6 mg/kg every 12 hours for 2 doses; followed by maintenance dose of 4 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Patients &lt;40 kg: 100 mg every 12 hours; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Patients &ge;40 kg: 200 mg every 12 hours; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     IDSA recommendations (Walsh, 2008): May consider oral therapy in place of I.V. with dosing of 4 mg/kg (rounded up to convenient tablet dosage form) every 12 hours; however, I.V. administration is preferred in serious infections since comparative efficacy with the oral formulation has not been established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Candidemia and other deep tissue",
"      <i>",
"       Candida",
"      </i>",
"      infections:",
"     </b>",
"     Treatment should continue for a minimum of 14 days following resolution of symptoms or following last positive culture, whichever is longer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Initial: Loading dose 6 mg/kg every 12 hours for 2 doses; followed by maintenance dose of 3-4 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Patients &lt;40 kg: 100 mg every 12 hours; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Patients &ge;40 kg: 200 mg every 12 hours; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     IDSA recommendations (Pappas, 2009): Initial: Loading dose: 400 mg every 12 hours for 2 doses; followed by 200 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Candidiasis, esophageal:",
"     </b>",
"     Oral: Treatment should continue for a minimum of 14 days, and for at least 7 days following resolution of symptoms:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients &lt;40 kg: 100 mg every 12 hours; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients &ge;40 kg: 200 mg every 12 hours; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Endophthalmitis, fungal:",
"     </b>",
"     I.V.: 6 mg/kg every 12 hours for 2 doses, then 3-4 mg/kg every 12 hours (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Scedosporiosis, fusariosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: Initial: Loading dose: 6 mg/kg every 12 hours for 2 doses; followed by maintenance dose of 4 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patients &lt;40 kg: 100 mg every 12 hours; maximum 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patients &ge;40 kg: 200 mg every 12 hours; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in patients unable to tolerate treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Dose may be reduced to 3 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Dose may be reduced in 50 mg decrements to a minimum dosage of 200 mg every 12 hours in patients weighing &ge;40 kg (100 mg every 12 hours in patients &lt;40 kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in patients receiving concomitant CYP450 enzyme inducers or substrates:",
"     </b>",
"     Children &ge;12 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclosporine: Reduce cyclosporine dose by one-half and monitor closely; upon discontinuation of voriconazole, monitor cyclosporine concentrations and escalate the cyclosporine dose as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Efavirenz: Oral: Increase maintenance dose of voriconazole to 400 mg every 12 hours and reduce efavirenz dose to 300 mg once daily; upon discontinuation of voriconazole, return to the initial dose of efavirenz",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omeprazole: Reduce omeprazole dose by one-half in patients maintained on &ge;40 mg/day of omeprazole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenytoin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Increase voriconazole maintenance dosage to 5 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Increase voriconazole dose to 400 mg every 12 hours in patients &ge;40 kg (200 mg every 12 hours in patients &lt;40 kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tacrolimus: Reduce tacrolimus dose to one-third of the original dose and monitor closely; upon discontinuation of voriconazole, monitor tacrolimus concentrations and escalate the tacrolimus dose as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     In  patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute, accumulation of the intravenous vehicle (cyclodextrin) occurs. After initial I.V. loading dose, oral voriconazole should be administered to these patients, unless an assessment of the risk:benefit to the patient justifies the use of I.V. voriconazole. Monitor serum creatinine and change to oral voriconazole therapy when possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. dosing",
"     <b>",
"      NOT",
"     </b>",
"     recommended since cyclodextrin vehicle is cleared at half the rate of voriconazole and may accumulate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild to moderate hepatic dysfunction (Child-Pugh Class A and B): Use standard loading dose regimen, then decrease maintenance dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh Class C): Not recommended for use unless benefit outweighs the risk; monitor closely for toxicity",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VFEND&reg;: 200 mg [contains cyclodextrin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VFEND&reg;: 40 mg/mL (70 mL) [contains sodium benzoate, sucrose; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VFEND&reg;: 50 mg, 200 mg [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes powder for suspension",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Correct any electrolyte disturbances such as hypokalemia, hypomagnesemia, or hypocalcemia prior to starting voriconazole therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer at least one hour before or one hour after a meal; shake suspension for approximately 10 seconds before use; do not mix suspension with other medications, flavoring agents, or other fluids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.:",
"     <b>",
"      Do not administer I.V. push;",
"     </b>",
"     voriconazole must be administered by I.V. infusion over 1-2 hours at a rate not to exceed 3 mg/kg/hour; final concentration for administration should be 0.5-5 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F234828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     WLR, D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     W with KCl 20 mEq,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, or D",
"     <sub>",
"      5",
"     </sub>",
"     WNS. Per manufacturer: Do not infuse",
"     <b>",
"      concomitantly",
"     </b>",
"     into same line or cannula with other drug infusions, including TPN or blood products. May be infused simultaneously with TPN through a separate I.V. line.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Anidulafungin, caspofungin, doripenem, vasopressin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Tigecycline.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablets: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Powder for oral suspension: Store in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) before reconstitution; protect from light. Reconstituted oral suspension is stable for 14 days at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not refrigerate or freeze reconstituted oral suspension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store unreconstituted vials at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); reconstituted 10 mg/mL I.V. solution should be used immediately after preparation since it contains no preservative. If not used immediately, the solution is stable for 24 hours at 2&deg;C to 8&deg; (36&deg;F to 46&deg;F). The reconstituted I.V. solution can be further diluted with NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     WLR, D",
"     <sub>",
"      5",
"     </sub>",
"     W with 20 mEq KCl/liter, D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     WNS, or",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS; voriconazole is incompatible with TPN, blood products, sodium bicarbonate, and electrolyte supplement infusions. Voriconazole can be infused at the same time as TPN, but must be infused in a separate line.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of invasive aspergillosis, especially in immunocompromised patients; treatment of candidemia in non-neutropenic patients; deep tissue",
"     <i>",
"      Candida",
"     </i>",
"     infections; esophageal candidiasis; treatment of serious fungal infections caused by",
"     <i>",
"      Scedosporium apiospermum",
"     </i>",
"     or",
"     <i>",
"      Fusarium",
"     </i>",
"     spp (including",
"     <i>",
"      Fusarium solanae",
"     </i>",
"     ) in patients intolerant of, or refractory to, conventional antifungal therapy (FDA approved in ages &ge;12 years).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14694838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Voriconazole may be confused with fluconazole",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F234827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, hallucinations, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, cholestatic jaundice",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Ocular: Visual changes (dose dependent; photophobia, color changes, increased or decreased visual acuity, or blurred vision)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Renal: Creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute tubular necrosis, adrenal cortical insufficiency, allergic reaction, alopecia, anaphylactoid reaction, ataxia, atrial arrhythmia, atrial fibrillation, AV block, bigeminy, bone marrow depression, bone necrosis, bradycardia, brain edema, bundle branch block, cardiac arrest, cardiomegaly, cardiomyopathy, cerebral hemorrhage, cerebral ischemia, cerebrovascular accident, chest pain, CHF, cholecystitis, cholelithiasis, chromatopsia, color blindness, coma, cyanosis, delirium, dementia, depersonalization, depression, diabetes insipidus, diarrhea, DIC, discoid lupus erythematosus, duodenal ulcer perforation, DVT, dyspnea, edema, encephalopathy, endocarditis, erythema multiforme, exfoliative dermatitis, extrapyramidal symptoms, fixed drug eruption, gastrointestinal hemorrhage, glucose tolerance decreased, Guillain-Barr&eacute; syndrome, hepatic failure, hepatitis, hydronephrosis, hypercholesterolemia, hypoxia, intestinal perforation, intracranial hypertension, lung edema, lymphadenopathy, lymphangitis, melanoma, MI, multiorgan failure, myasthenia, myopathy, nephritis, nephrosis, neuropathy, night blindness, nodal arrhythmia, oculogyric crisis, optic atrophy, optic neuritis, orthostatic hypotension, osteomalacia, osteoporosis, palpitation, pancreatitis, papilledema, paresthesia, peripheral edema, peritonitis, petechia, photosensitivity, pleural effusion, pseudomembraneous colitis, pseudoporphyria, psychosis, pulmonary embolus, purpura, QT interval prolongation, renal failure (acute), respiratory distress syndrome, retinal hemorrhage, seizure, sepsis, spleen enlarged, squamous cell carcinoma, Stevens-Johnson syndrome, suicidal ideation, supraventricular extrasystoles, supraventricular tachycardia, syncope, thrombophlebitis, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis, uremia, urinary retention, uveitis, vasodilation, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to voriconazole or any component; concurrent therapy with rifampin, carbamazepine, long-acting barbiturates (phenobarbital, mephobarbital), sirolimus, CYP3A4 substrates (terfenadine, astemizole, cisapride, pimozide, quinidine), ritonavir (high-dose: &ge;800 mg/day), efavirenz [with standard (eg, not adjusted) voriconazole and efavirenz doses]), ergot alkaloids, rifabutin, St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in patients with hypersensitivity to other azole antifungal agents since cross-reaction may occur but has not been established; use with caution in patients with severe renal or hepatic impairment; modify dosage in patients with mild to moderate hepatic cirrhosis (Child-Pugh class A and B); avoid administration of voriconazole injection in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute since I.V. formulation contains sulfobutyl ether beta-cyclodextrin (SBECD) which may accumulate in renal insufficiency. Infusion-related anaphylactoid-type reactions (chest tightness, dyspnea, faintness, fever, flushing, nausea, pruritus, rash, sweating, and tachycardia) have been reported (uncommon); consider stopping infusion if this occurs. Use with caution in patients (children and adults) at risk for acute pancreatitis (eg, recent chemotherapy or hematopoietic stem cell transplantation); postmarketing occurrences of pancreatitis in children have been reported; pancreatic function should be monitored.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious hepatic reactions including hepatitis, cholestasis, fulminant hepatic failure, and death have been reported. Liver function test abnormalities may be associated with higher plasma drug concentrations and/or doses; dosage adjustment or discontinuation of therapy may be required. Visual changes such as blurred vision, photophobia, changes in visual acuity and color have been reported in clinical trials; postmarketing cases of optic neuritis and papilledema (lasting &gt;1 month) have also been reported. Patients should be warned to avoid tasks which depend on vision, including operating machinery or driving; the effect on vision with long-term administration (beyond 28 days) is unknown and should be monitored. QT interval prolongation has been associated with voriconazole use; rare cases of arrhythmia (including torsade de pointes), cardiac arrest, and sudden death have been reported, usually in seriously ill patients with comorbidities and/or risk factors (eg, prior cardiotoxic chemotherapy, cardiomyopathy, electrolyte imbalance, or concomitant QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs). Use with caution in these patient populations; correct electrolyte abnormalities (eg, hypokalemia, hypomagnesemia, hypocalcemia) prior to initiating therapy. Rare cases of malignancy (melanoma, squamous cell carcinoma) have been reported in patients (mostly immunocompromised) with prior onset of severe photosensitivity reactions and exposure to long-term voriconazole therapy. Other serious exfoliative cutaneous reactions, including Stevens-Johnson syndrome, have also been reported. Patients should avoid strong, direct exposure to sunlight; may cause photosensitivity, especially with long-term use. Discontinue use in patients who develop an exfoliative cutaneous reaction or a skin lesion consistent with squamous cell carcinoma or melanoma. Periodic total body skin examinations should be performed, particularly with prolonged use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     If used during pregnancy, the patient should be informed that voriconazole may cause fetal harm. Voriconazole tablets contain lactose; avoid use in patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Voriconazole oral suspension contains sucrose; avoid use in patients with rare hereditary problems of fructose intolerance, sucrose-isomaltase deficiency or glucose-galactose malabsorption.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Voriconazole is metabolized by cytochrome P450 enzymes resulting in interactions with other drugs. Due to potential serious and/or life-threatening drug interactions, some drugs are contraindicated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Voriconazole oral suspension contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use voriconazole oral suspension containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F234816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (moderate), CYP2C9 (moderate), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Vinca Alkaloids): Voriconazole may enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Astemizole: Voriconazole may increase the serum concentration of Astemizole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May decrease the serum concentration of Voriconazole. Atazanavir may increase the serum concentration of Voriconazole. Voriconazole may decrease the serum concentration of Atazanavir. Management: Voriconazole should not be used in a patient who is being treated with ritonavir-boosted atazanavir unless the benefits of the combination outweigh the potential risks.  Extra monitoring for both loss of effectivness and toxicity is warranted.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Voriconazole may increase the serum concentration of AtorvaSTATin.  Management: Monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities) during concomitant treatment, and reduce atorvastatin dose when possible. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: Voriconazole may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Voriconazole.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Methohexital; PENTobarbital; Secobarbital; Thiopental.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).  Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Quazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers.  Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cinacalcet.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Cobicistat. Management: Careful consideration of the risk/benefit ratio for voriconazole use is recommended prior to its use in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Voriconazole may decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Voriconazole may increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): Voriconazole may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with voriconazole.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Topical): Voriconazole may increase the serum concentration of Diclofenac (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Voriconazole may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOCEtaxel: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Voriconazole may increase the serum concentration of Eletriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Voriconazole may increase the serum concentration of Elvitegravir.  Management: Careful consideration of the risk/benefit ratio for voriconazole use is recommended prior to its use in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Voriconazole may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Voriconazole may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Voriconazole may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Voriconazole may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eszopiclone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Eszopiclone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Voriconazole may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosaprepitant. Specifically, concentrations of aprepitant are likely to be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This specifically applies to oral antifungal administration, and the interaction may be different depending on specific dosage form being used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen: Voriconazole may increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Losartan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meloxicam: Voriconazole may increase the serum concentration of Meloxicam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Voriconazole may increase the serum concentration of Methadone.  Management: Methadone dose reduction may be necessary when used with voriconazole.  With any concurrent use, monitor patients closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Voriconazole may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Voriconazole may increase the serum concentration of Nelfinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OxyCODONE: Voriconazole may increase the serum concentration of OxyCODONE.  Management: A reduced oxycodone dose may be necessary with concurrent voriconazole.  Increased frequency and duration of monitoring for oxycodone-related adverse effects is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin. Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors. Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine.  Management: Itraconazole, voriconazole, and posaconazole are specifically contraindicated with quinidine.  Use of quinidine with any azole antifungal may require quinidine dose adjustment and should be done with caution and close monitoring.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Repaglinide.  Management: Concurrent use of an azole antifungal with both repaglinide and gemfibrozil should be avoided.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Non-Nucleoside): Voriconazole may increase the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Voriconazole.  Management: Consider avoiding when possible. Use efavirenz with voriconazole only if voriconazole is dosed at 400 mg every 12 hours and efavirenz is dosed at 300 mg daily (adult doses) throughout therapy. Avoid Atripla (efavirenz/emtricitabine/tenofovir).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Delavirdine; Etravirine; Rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: Voriconazole may increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Voriconazole. Management: Concurrent voriconazole and high-dose ritonavir (adult doses of 400 mg every 12 hrs or greater) is contraindicated.  Voriconazole with lower-dose ritonavir should be avoided unless benefits outweigh risk of inadequate voriconazole concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Voriconazole may increase the serum concentration of Sildenafil.  Management: Concurrent voriconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent voriconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Voriconazole may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Solifenacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Voriconazole may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of SUNItinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Voriconazole may increase the serum concentration of Tacrolimus (Systemic).  Management: When starting voriconazole in patients already receiving tacrolimus, reduce tacrolimus dose to one-third of the original dose. Monitor tacrolimus blood levels closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Voriconazole may increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Voriconazole. Telaprevir may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and voriconazole should be avoided due to the uncertain impact on drug concentrations and effects unless the benefit/risk ratio justifies its use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Voriconazole may increase the serum concentration of Terfenadine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Voriconazole may increase the serum concentration of Vardenafil.  Management: Limit vardenafil dosing to a  maximum of 2.5 mg per 24 hours  in patients receiving concurrent therapy with strong CYP3A4 inhibitors, such as voriconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Venlafaxine: Voriconazole may enhance the adverse/toxic effect of Venlafaxine. Voriconazole may increase the serum concentration of Venlafaxine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Voriconazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ziprasidone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Zolpidem.  Management: Consider using a lower starting dose of zolpidem in patients receiving systemic azole antifungals. Monitor patients closely for increased magnitude and/or duration of zolpidem effects when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1050645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High fat meals reduce the extent of absorption by 24% for tablets and 37% for the oral suspension; avoid grapefruit juice (may increase voriconazole serum concentrations)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F234755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F234765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Voriconazole can cause fetal harm when administered to a pregnant woman. Voriconazole was teratogenic and embryotoxic in animal studies, and lowered plasma estradiol in animal models. Women of childbearing potential should use effective contraception during treatment. Should be used in pregnant woman only if benefit to mother justifies potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, periodic renal function tests (particularly serum creatinine), hepatic function tests, and bilirubin; monitor visual activity, visual field, and color perception if treatment course continues &gt;28 days; ECG in select patients; pancreatic function in patients at risk for acute pancreatitis; voriconazole trough levels in patients exhibiting signs of toxicity or not responding to treatment; total body skin examination yearly or more frequently if lesions occur",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10255826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trough: 1-5 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits fungal cytochrome P450-dependent 14a-sterol demethylase, an essential enzyme in ergosterol biosynthesis resulting in the inhibition of fungal cell membrane formation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive tissue distribution; CSF concentration ~50% of plasma concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : 4.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 58%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized by cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4 to voriconazole N-oxide (minimal antifungal activity); CYP2C19 is significantly involved in metabolism of voriconazole; CYP2C19 exhibits genetic polymorphism (15% to 20% Asians may be poor metabolizers of voriconazole; 3% to 5% Caucasians and African Americans may be poor metabolizers); in pediatric patients (2-12 years), metabolic clearance faster than adults (Walsh, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:  96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Terminal (dose-dependent): 6-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;2% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/39/33397?source=see_link\">",
"      see \"Voriconazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid drinking grapefruit juice while taking voriconazole. Avoid driving at night or performing hazardous tasks while taking voriconazole; it may cause blurred vision and/or photophobia. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Women of childbearing age should use effective contraception during treatment to avoid pregnancy. Inform physician of serious change in heart rate or rhythm, vision changes, yellowing of skin or eyes, itching, flu-like symptoms, nausea, vomiting, feeling tired, seizures, or trouble breathing.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cesaro S, Strugo L, Alaggio R, et al, \"Voriconazole for Invasive Aspergillosis in Oncohematological Patients: A Single-Center Pediatric Experience,\"",
"      <i>",
"       Support Care Cancer",
"      </i>",
"      , 2003, 11(11):722-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/13680324/pubmed\" id=\"13680324\" target=\"_blank\">",
"        13680324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cowen EW, Nguyen JC, Miller DD, et al, \"Chronic Phototoxicity and Aggressive Squamous Cell Carcinoma of the Skin in Children and Adults During Treatment With Voriconazole,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2010, 62(1):31-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/19896749/pubmed\" id=\"19896749\" target=\"_blank\">",
"        19896749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frankenbusch K, Eifinger F, Kribs A, et al, \"Severe Primary Cutaneous Aspergillosis Refractory to Amphotericin B and the Successful Treatment With Systemic Voriconazole in Two Premature Infants With Extremely Low Birth Weight,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 2006, 26(8):511-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/16871222/pubmed\" id=\"16871222\" target=\"_blank\">",
"        16871222",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kohli V, Taneja V, Sachdev P, et al, \"Voriconazole in Newborns,\"",
"      <i>",
"       Indian Pediatr",
"      </i>",
"      , 2008, 45(3):236-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/18367773/pubmed\" id=\"18367773\" target=\"_blank\">",
"        18367773",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCarthy KL, Playford EG, Looke DF, et al, \"Severe Photosensitivity Causing Multifocal Squamous Cell Carcinomas Secondary to Prolonged Voriconazole Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 44(5):e55-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/17278050/pubmed\" id=\"17278050\" target=\"_blank\">",
"        17278050",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller DD, Cowen EW, Nguyen JC, et al, \"Melanoma Associated With Long-Term Voriconazole Therapy: A New Manifestation of Chronic Photosensitivity,\"",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 2010, 146(3):300-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/20083676/pubmed\" id=\"20083676\" target=\"_blank\">",
"        20083676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neely M, Rushing T, Kovacs A, et al, \"Voriconazole Pharmacokinetics and Pharmacodynamics in Children,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(1):27-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/19951112/pubmed\" id=\"19951112\" target=\"_blank\">",
"        19951112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, \"Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Romero AJ, Pogamp PL, Nilsson LG, et al, &ldquo;Effect of Voriconazole on the Pharmacokinetics of Cyclosporine in Renal Transplant Patients,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2002, 71(4):226-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/11956505/pubmed\" id=\"11956505\" target=\"_blank\">",
"        11956505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Santos RP, S&aacute;nchez PJ, Mejias A, et al, \"Successful Medical Treatment of Cutaneous Aspergillosis in a Premature Infant Using Liposomal Amphotericin B, Voriconazole and Micafungin,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2007, 26(4):364-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/17414408/pubmed\" id=\"17414408\" target=\"_blank\">",
"        17414408",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scott LJ and Simpson D, \"Voriconazole: A Review of its Use in the Management of Invasive Fungal Infections,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2007, 67(2):269-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/17284090/pubmed\" id=\"17284090\" target=\"_blank\">",
"        17284090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steinbach WJ, \"Antifungal Agents in Children,\"",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 2005, 52(3):895-915.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/15925667/pubmed\" id=\"15925667\" target=\"_blank\">",
"        15925667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al, \"Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(3):327-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/18177225/pubmed\" id=\"18177225\" target=\"_blank\">",
"        18177225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Driscoll T, Milligan PA, et al, \"Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2010, 54(10):4116-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/20660687/pubmed\" id=\"20660687\" target=\"_blank\">",
"        20660687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Karlsson MO, Driscoll T, et al, &ldquo;Pharmacokinetics and Safety of Intravenous Voriconazole in Children After Single- or Multiple-Dose Administration,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2004, 48(6):2166-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/15155217/pubmed\" id=\"15155217\" target=\"_blank\">",
"        15155217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Lutsar I, Driscoll T, et al, &ldquo;Voriconazole in the Treatment of Aspergillosis, Scedosporiosis and Other Invasive Fungal Infections in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2002, 21(3):240-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/12005089/pubmed\" id=\"12005089\" target=\"_blank\">",
"        12005089",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Pappas P, Winston DJ, et al, &ldquo;Voriconazole Compared With Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients With Neutropenia and Persistent Fever,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(4):225-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/60/12234/abstract-text/11807146/pubmed\" id=\"11807146\" target=\"_blank\">",
"        11807146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12885 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-F6CCE2A0D3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12234=[""].join("\n");
var outline_f11_60_12234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234784\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855140\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050636\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675816\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050628\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234759\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234745\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050640\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234828\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050631\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050639\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14694838\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234827\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050643\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050627\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050626\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234816\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234753\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050645\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234755\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234765\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050635\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10255826\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050625\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050642\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050633\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12885\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12885|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=related_link\">",
"      Voriconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/39/33397?source=related_link\">",
"      Voriconazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_60_12235="Indications for fomepizole or ethanol therapy";
var content_f11_60_12235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for antidotal therapy with fomepizole or ethanol",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Documented serum methanol or ethylene glycol concentration &gt;20 mg/dL (methanol SI equivalent 6.2 mmol/L; ethylene glycol SI equivalent 3.2 mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Documented recent history of ingesting toxic amounts of methanol or ethylene glycol and serum osmol gap &gt;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Strong clinical suspicion of methanol or ethylene glycol poisoning and at least two of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        a) Arterial pH &lt;7.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        b) Serum bicarbonate &lt;20 meq/L (mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        c) Osmol gap &gt;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        d) Urinary oxalate crystals present",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12235=[""].join("\n");
var outline_f11_60_12235=null;
var title_f11_60_12236="Representative costs to treat venous disease";
var content_f11_60_12236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Representative costs to treat venous disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Supply",
"       </td>",
"       <td class=\"subtitle1\">",
"        Charge, US dollars",
"       </td>",
"       <td class=\"subtitle1\">",
"        Life-span of item",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Compression stockings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Over the counter knee high (&lt;15 mmHg compression)",
"       </td>",
"       <td>",
"        $30 per pair",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        30-40 mmHg knee high, fitted",
"       </td>",
"       <td>",
"        $90 per pair",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        30-40 mmHg thigh high, fitted",
"       </td>",
"       <td>",
"        $100 per pair",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Higher grade, custom",
"       </td>",
"       <td>",
"        $200 per pair",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jobst&reg; Ulcer Care",
"       </td>",
"       <td>",
"        $80",
"       </td>",
"       <td>",
"        6 months*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CircAid&reg; legging",
"       </td>",
"       <td>",
"        $700 per extremity",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unna Boot Kit",
"       </td>",
"       <td>",
"        $7",
"       </td>",
"       <td>",
"        1 to 2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Four layer compression wrap",
"       </td>",
"       <td>",
"        $32",
"       </td>",
"       <td>",
"        1 to 2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DuoDerm&reg; occlusive dressing (4 cm x 4 cm)",
"       </td>",
"       <td>",
"        $4 per sheet",
"       </td>",
"       <td>",
"        3 to 5 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonadherent dressing (2 cm x 3 cm)",
"       </td>",
"       <td>",
"        $0.14 per sheet",
"       </td>",
"       <td>",
"        1 per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermittent pneumatic compression",
"       </td>",
"       <td>",
"        $4000 per month",
"       </td>",
"       <td>",
"        Not applicable",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Decreased lifespan when used with to treat active ulcer.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12236=[""].join("\n");
var outline_f11_60_12236=null;
var title_f11_60_12237="S-LANSS";
var content_f11_60_12237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    S-LANSS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         1.",
"        </strong>",
"        In the area where you have pain, do you also have 'pins and needles', tingling or prickling sensations?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        a) NO - I don't get these sensations",
"       </td>",
"       <td>",
"        (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        b) YES - I get these sensations often",
"       </td>",
"       <td>",
"        (5)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         2.",
"        </strong>",
"        Does the painful area change colour (perhaps looks mottled or more red) when the pain is particularly bad?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        a) NO - The pain does not affect the colour of my skin",
"       </td>",
"       <td>",
"        (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        b) YES - I have noticed that the pain does make my skin look different from normal",
"       </td>",
"       <td>",
"        (5)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         3.",
"        </strong>",
"        Does your pain make the affected skin abnormally sensitive to touch? Getting unpleasant sensations or pain when lightly stroking the skin might describe this.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        a) NO - The pain does not make my skin in that area abnormally sensitive to touch",
"       </td>",
"       <td>",
"        (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        b) YES - My skin in that area is particularly sensitive to touch",
"       </td>",
"       <td>",
"        (3)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         4.",
"        </strong>",
"        Does your pain come on suddenly and in bursts for no apparent reason when you are completely still? Words like 'electric shocks', jumping and bursting might describe this.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        a) NO - My pain doesn't really feel like this",
"       </td>",
"       <td>",
"        (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        b) YES - I get these sensations often",
"       </td>",
"       <td>",
"        (2)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         5.",
"        </strong>",
"        In the area where you have pain, does your skin feel unusually hot like a burning pain?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        a) NO - I don't have burning pain",
"       </td>",
"       <td>",
"        (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        b) YES - I get burning pain often",
"       </td>",
"       <td>",
"        (1)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         6.",
"        </strong>",
"        Gently",
"        <strong>",
"         rub",
"        </strong>",
"        the painful area with your index finger and then rub a non-painful area (for example, an area of skin further away or on the opposite side from the painful area). How does this rubbing feel in the painful area?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        a) The painful area feels no different from the non-painful area",
"       </td>",
"       <td>",
"        (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        b) I feel discomfort, like pins and needles, tingling or burning in the painful area that is different from the non-painful area",
"       </td>",
"       <td>",
"        (5)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         7.",
"        </strong>",
"        Gently",
"        <strong>",
"         press",
"        </strong>",
"        on the painful area with your finger tip then gently press in the same way onto a non-painful area (the same non-painful area that you chose in the last question). How does this feel in the painful area?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        a) The painful area does not feel different from the non-painful area",
"       </td>",
"       <td>",
"        (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        b) I feel numbness or tenderness in the painful area that is different from the non-painful area",
"       </td>",
"       <td>",
"        (3)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         SCORING: A score of 12 or more suggests pain of predominantly neuropathic origin.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Bennet, MI, Smith, BH, Torrance, N, et al. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain 2005; 6:149. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12237=[""].join("\n");
var outline_f11_60_12237=null;
var title_f11_60_12238="Initial management of dyspepsia";
var content_f11_60_12238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Figure 1. Initial management of dyspepsia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 241px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NSAID: nonsteroidal antiinflammatory drug; COX: cyclooxygenase; GERD: gastroesophageal reflux disease; PPI: proton pump inhibitor.",
"    </div>",
"    <div class=\"reference\">",
"     Talley NJ. Gastroenterology 2005; 129:1753.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12238=[""].join("\n");
var outline_f11_60_12238=null;
var title_f11_60_12239="Pacemaker algorithm sinus node dysfunction";
var content_f11_60_12239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Selection of pacemaker systems for patients with sinus node dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 452px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Decisions are illustrated by diamonds. Shaded boxes indicate type of pacemaker.",
"    <div class=\"footnotes\">",
"     AV: atrioventricular.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51(21):e1-e62. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 2008 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_60_12239=[""].join("\n");
var outline_f11_60_12239=null;
